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Abstract

a-Amylase is a heterogeneous polypeptide, primarily found in the Salivary and
Pancreatic glands, giving rise to two isoenzymes, namely Salivary- and Pancreatic-type
Amylases. Total a-Amylase activity measurements are routinely carried out in hospital
laboratories to aid in the diagnosis of diseases of the pancreas and in the investigation
of pancreatic function in patients with severe abdominal pains. With the development
and wide availabihty of modem chromogenic ohgosaccharide substrates specific for
Amylase, assays have become more sensitive, rapid and easier to use.

Differentia] Amylase Isoenzyme assays ware developed to distinguish isoenzyme
levels.

Several methods were developed for isoenzyme determination.

Selective Inhibition was found to be rapid, selective and sensitive.
inhibitors were tested, W.G.I. and DOG3.

Of these.

Two selective

The inhibition from DOG3 lacked the

specificity required for a selective assay, however, the W.G.I. inhibited the Sahvary
and Pancreatic isoenzymes by 88% and 13% respectively. Upon incorporation with a
chromogenic ohgosaccharide such as EPS or CNPG3, an assay was developed which
could be used in the clinical field for rapid differentiated analysis of the two isoenzymes
of Amylases.

Comparative trials were carried out using a commercially available kit incorporating
monoclonal antibodies against S.Amylase.

However, the cost of reagents was a

significant drawback.

In conclusion, both the EPS and CNPG3 Assay’s incorporating the W.G.I., provide
conclusive isoenzyme analysis in addition to being effective, sensitive and rapid
techniques. In addition these assays have the appropriate accuracy and precision.
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1.1

Introduction

AJpha-amylase or alpha-l-4-glucan-4-glucanohydrolase (EC 3.2.1.1) was the first
onzymic action ever described, when Kirchhofif in 1811 discovered the digestion of starch
by wheat extracts. It was not until 1831 that the enzyme was found to be present in
s:aliva by Leuchs and in serum by Magendie in 1846 and in urine by Cohcheim in 1863.

Assays were developed by the late nineteenth century for the measurement of total
amylase activity. These methods shall be discussed in detail later. However due to the
ease of purification and measurement of amylase, classical early studies of the enzyme’s
kinetics by Henri in 1902 and Michaelis in 1914 proved a valuable insight into the
mechanism of enzyme reactions.

1.2

Biochemistry of Amylase

The amylase protein is a single polypeptide and it's molecular weight is estimated to be
between 55,000 - 60,000D (1). It has a pH optimum of 6.9. a-Amylase catalyses the
enzymatic hydrolysis of random internal a-l,4-glycosidic linkages in starch, glycogen and
other glucose polymers. It is an endoglycosidase which retains the a-configuration in it's
reaction products (2). a-Amylase can cleave any internal a-l,4-glycosidic bond except
for the terminal bond on the reducing end of the substrate.

Amylase is a secreted protein. The initial product of translation is a pre-amylase which
has a M.W. some 1500 - 2000D greater than the active protein.

Partial amino acid

sequencing of this additional N-terminal segment showed it to be rich in hydrophobic
amino acids and thus it may function as a signal peptide directing secretion of the protein
(3).

Amylase is a calcium-requiring metallo-enzyme with at least one calcium tightly bound per
protein molecule and the presence of the calicum is required for full enzymatic activity(4).
The calicum appears to confer an increased strength to the structure of amylase providing
protection against proteolysis.

The a-amylase family has a (p/a)8 - or TIM barrel catalytic domain with a highly
symmetrical fold of eight inner, parallel p-strands surrounded by eight helices. The aamylase family is subdivided based upon the presence of a small separate folding module
‘domain B’. This is located between P-strand 3 and a-helix 3 in the (p/a)8 fold (5).

Figure 1:

Connectivity diagram of secondary structure elements in the (p/a)8-barrel
(domain A) Circles designate helices and squares p-strands.
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1.3

Regulation Mechanism of Mammalian a-Amyiase

Ishikawa, K. et al. (6) discovered three active histidine residues (His 101, 201, 299)
around the catalytic site of human pancreatic amylase in addition to two catalytic aspartic
acid residues (Asp 197, 300). His 201 as can be seen in fig.2 is located with subsite 5 and
is found to interact with a bound substrate to induce activity. The binding of a chloride
ion causes an increase in enzyme activities and is bound to a peptide loop which is located
along the catalytic site of the substrate.
I

II

III

IV

V

Figure 2; Active site of Amylase
and it’s point of interaction with the
catalyitc site of a substrate.
Arg337

It was proven that the catalytic activity of mammalian a-amylase is controlled by the
interaction of the substrate, which is sterically recognized by a binding site through a key
a.a. residue in the same site. This loose substrate recognizability lacking specific hydrogen
bonding may be of physiological importance by allowing the a-amylases the abillity to
digest modified oligosaccharides in foodstuff (7).

Starches of various sources and composition have different susceptibilities to digestion by
amylases.

For total amylase activity, amylopectin is a better substrate than glycogen

which in turn is a better substrate than amylose (8).

Amylases have been identified from diflferent sources primarily the salivary and pancreatic
glands giving rise to two fundamental amylase isoenzymes.

The two isoenzymes,

salivary- and pancreatic-type amylases differ in weight by 1000 to 4000D with the
pancreatic isoenzyme having a lesser mass, as determined by SDS-PAGE.

The

pancreatic and the salivary isoenzymes are seen to be quite similar by amino acid
composition. Peptide mapping has revealed that only a few distinct peptides are umque
to either isoenzyme (9).

By improved electrophoretic separations, there was found to be a significant degree of
heterogeneity within both isoenzymes. There was found to be 4 isoenzymes within the
salivary amylase and 3 isotypes within the pancreatic type amylase (10,11). The current
explanations for this heterogeneity is as summarised (12).

Sources of Amvlase Heterogeneity
A.

B.

C.

Genetic Loci
1.

Amy 1 (Salivary)

2.

Amy 2 (Pancreatic)

Allelic Variation
1.

Salivary - 12 alleles

2.

Pancreatic - 6 alleles

Post-Translation Modifications
1.
2.

Glycosylation
Deglycosylation

3.

Deamidation
- Enzymatic
- Non-enzymatic

Under the heading of post-translational modifications only the salivary isoenzyme has the
ability to be glycosylated.

Deamidation refers to the ability of changing the overall

charge to negative by the removal of the amide group from the a.a.'s glutamine and
asparagine. All three of these methods of post-translational modifications result from
either enzymatic or non-enzymatic reactions. Enzymatic mechanisms for deamidation
may involve two particular enzymes; peptidoglutaminases or a pancreatic deamidase (13)
resulting in more anodic forms of amylase.

Non-enzymatic mechanisms such as

incubation or storage have been found to cause the appearance of bands that also
migrated anodally during electrophoresis (14).

1.4

Tissue Distribution of Amylases

Between both types of isoenzymes, amylase has a wide tissue distribution with the
highest activities of the pancreatic and salivary types being found in the exocrine pancreas
and salivary glands respectively. However, amylase activity is also found to be present in
a variety of other sources. These include lung, leukocytes, milk, tears, liver, prostate
gland and amniotic fluid (15). However, it is debated as to whether these tissues actually
express amylase genes or just absorb the enzyme from circulation. Serum amylase is a
combination of both salivary and pancreatic-type isoenzymes.

It was observed by

Mellersh, A. et al. (16) that normal human saliva had inhibition properties against the
micro-organism Neisseria gonorrhoeae. It was concluded that amylase may play a role
in the host defence mechanisms, by modifying the carbohydrate portions of receptors or
structures on the micro-organisms. This idea is supported by the presence of amylase in
human leukocytes and thrombocytes.

1.5

Clinical Significall^^c

Measurement of amylase activity is of great significance for use in the diagnosis of
diseases of the pancreas and in the investigation of pancreatic function. However, due to
the wide tissue distribution of amylase there is a significant lack of clinical specificity and
sensitivity.

There are two types of pancreatitis, acute pancreatitis and chronic pancreatitis.

The

former displays a transient rise in the level of serum amylase activity occurring within two
to twelve hours of the onset. However these levels return to nonnal by the third or
fourth day. The magnitude of the serum enzyme activity elevation is not related to the
severity of damage to the pancreas. A second point to note is that as serum levels rise, a
subsequent rise in urinary amylase can also be found. In chronic cases, both serum and
urine enzyme activities are found to be subnormal (17).

In acute pancreatitis cases, the pain has been described as an "internal burn", however
this can be the case in many abdominal disorders of which acute pancreatitis accounts for
only 10% to 15% (18).

The disease of acute pancreatitis ranges from mild pancreatic oedema to multi-organ
system failure, so diagnosis proves to be the major diagnostic challenge. Furthermore
due to the location of the organ deep within the abdominal cavity, direct examination of
the organ is impossible. Therefore surgery is rarely used solely for diagnosis as the risk
to the patient is too high.
ultrasound

or

Alternative data can be obtained from procedures such as

laparoscopy( 19)

To aid diagnosis of acute pancreatitis, laboratory enzyme assays have been developed.
The range of pancreatic enzyme tests includes amylase isoenzymes, lipase isoenzymes.

trypsin and phospholipase A. Overall, amylase and lipase are the most frequently ordered
tests for abdominal pain.

Amylase and lipase tests are usually ordered together in cases of suspected acute
pancreatitis. Lipase (triacylglycerol acylhydrolase; EC 3.1.1.3) is a 48-kDa glycoprotein
that preferentially hydrolyses glycerol esters of long-chain fatty acids at the C-1 and C-3
position of the glycerol backbone (20). Lipase enzyme has a number of advantages over
amylase as a possible marker of pancreatic diseases.

An elevation of lipase is more specific to pancreatic disorders than amylase elevation. It
is elevated to a greater extent and exists in the blood circulation for a longer length of
time than amylase. However despite these advantages, no clear and prompt diagnostic
test has been developed to satisfactorily meet clinical requirements. It requires a two
hour incubation step which rules out it's use as an emergency test.

However, it has been proven (21) that serum lipase has twice the specificity and the same
sensitivity as amylase for the diagnosis of pancreatic disorders. Unfortunately, due to
some contradicting results found, such as in cases of chronic pancreatitis, widespread
acceptance of the lipase assay as the sole detector of acute pancreatitis has been upset.

As a thorough detection method, amylase and lipase tests should be ordered together,
and performed twice or three times daily for two to three successive days (22) for the
diagnosis of the severity, predicting complications and for estimation of treatment of
acute pancreatitis (23).

1.6

Hyperamylasuria differs from hyperamylasemia where an elevated amylase

activity is found in urine as opposed to the serum.

Causes bf Hypcraniyl^setihla and / or Hyperarnylasur^^^
A. Pancreatic Disease

1. Pancreatitis — Acute
— Chronic
2. Pancreatic Carcinoma
3. Pancreatic Trauma

B. Non-Pancreatic Disorders

1. Tumor Hyperamylasemia
2. Renal Insufficiency
3. Salivary Gland Lesions — Mumps
— Drugs

C. Disorders of Complex Origin

1. Biliary Tract Disease
2. Intraabdominal Diseases — Peritonitis
— Appendicitis
” Peptic Ulcer
3. Bums
4. Diabetic Ketoacidosis
5. Renal Transplantation
6. Prostatic Disease
7. Post-operative Hyperamylasemia

Amylase is excreted from the body by the renal system.
where it may be partially reabsorbed.
hyperamylasemia may occur.

It is filtered by the kidneys,

In the case where the renal system fails

It has been found (24) that the renal elimination of

pancreatic amylase is at a faster rate than that of the isotype salivary amylase and so a
build up of S-isotype occurs in the serum leading to hyperamylasemia in Chronic Renal
Failure (CRF) patients.

A further complication may occur upon renal failure. The serum amylase can lead to a
condition called macroamylasemia where upon the amylase forms molecular complexes
with immunoglobulins. This creates a larger molecule and thus prevents free passage of
the enzyme through the glomerulus of the kidneys. Therefore urine amylase clearance
drops and the serum amylase activity rises. Macroamylase appears to form an antibody ;
antigen complex with the binding occurring at the Fab portion of the immunoglobulin.
The most common immunoglobulins found in the complex are IgA and IgG.
Macroamylasemia is considered a benign disease (25) as it's presence appears to have no
clinical effects or diagnostic value.

The main concern is the potential of misleading

diagnosis of high amylase activity values. The hyperamylasemia due to macroamylasemia
can interfere with "true" amylase values for suspect acute pancreatitis patients with
severe abdominal pain and vomiting.

So an assay was required to measure true hyperamylasemia values with minimum
interference’s from macroamylase complexes.

Rosenblum, J.L. et al . (26) observed

macrocmylasemic samples producing a higher activity with smaller oligosaccharide
substrates than against substrates such as starch or amylopectin. So where discrepancies
occur n samples especially in cases of high activity values, macroamylasemia must be
considered and performing the assay with large polysaccharides as substrates if possible
is reccmmended.

Overall CRF may lead to the potential misdiagnosis of a pancreatic

disorder (20). All of these further complications can lead to a difficulty in correctly
diagnosing acute pancreatitis in patients with CRF (27).

Further non pancreatic disorders leading to elevated amylase levels are neoplastic
hyperamylasemia cases, such as tumours of the lung and serous tumours of the ovary. It
was reported as early as 1951, that increased serum amylase was detected in
bronchogenic carcinomas (28).

It was originally theorised that many lung carcinomas

especially small cell carcinomas may have produced elevated levels of enzymes,
hormones and tumour antigens.

However, Lenler-Peterson et al

proved by

immunohistochemical experiments that hyperamylasemia could not be used as a tumour
marker for lung cancer (29). Their possible explanation was that the tissue salivary- like
type amylase was synthesised, but not secreted by the tumour cells.

Serous tumour, is the most common ovarian cancer. It was found that the cyst fluid from
tumour contains a large amylase activity. However, Zakowski et aL confirmed the
existence of an "acidic amylase" by means of isolation via column chromatography
techniques (30). This data provides sufficient proof of a useful marker of Serous Ovarian
Tumours. However, the main drawback feature of this process is the incubation time of
the samples - up to twenty-six hours is required before the total amylase and the high-salt
amylase can be assayed.
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1.7

Methods of Determination

It has been estimated that there are over two hundred methods for determining total
amylase activity in serum.

For developing an enzyme assay, the reaction principle is

examined. Simplified, an enzyme reaction is as follows :
S + E------------ > P + E
For the activity of an enzyme to be measured, either the increase in product or the
decrease in substrate must be determined. Whichever principle is used, the International
Committee on Enzymes has devised a universal definition for quantifying enzyme activity
- The International Unit. This may be defined as ;

One International Unit (1U) of enzyme is that amount that catalyses the
formation of Ipmole of product per minute under defined conditions.

Theoretically, there are three main types of assays for a-amylase :
(1)

Amyloclastic

(2)

Saccharogenic

(3)

Chromogenic

With the demand for rapid, sensitive and selective kits, the movement forward is for
liquid stable chromophore bound substrates. Therefore when the chromophore is cleaved
by direct action of the enzyme the colour development is directly proportional to the
enzyme activity.

The Expert Panel on Enzymes of the International Federation of Clinical Chemists
(IFCC) recommends that an amylase method should (31):
•

Be a continuous - monitoring technique with zero- order kinetics.

•

Have a clearly defined substrate and reaction products, that are not affected by
changing reaction conditions.
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•

Generate a product which absorbs at a constant wavelength.

•

Displays high rates of conversion.

•

Have a lag phase that does not exceed 3 mins.

•

Be free of interference by endogenous glucose.

•

Allow measurements of samples containing catalytic concentrations of up to five
times the upper reference range.

1.7.1

Amyloclastic Assays

Under the heading of Amyloclastic assays, several variations exist for the measurement of
Amylase activity. These include iodometric, turbidimetric and nephelometric methods.
These three procedures all act under the same principle of measuring the decrease in
substrate.

The principle of Wohlgemuth's iodometric method is based upon using starch as the
substrate. Starch is composed of a mixture of amylose and amylopectin. The molecular
size of both fractions is variable.

The enzyme is allowed to hydrolyse various

concentrations of starch present for a fixed period of time. The activity of enzyme is
calculated by that concentration of starch which is completely hydrolysed.

An improvement upon this method is Von Loon's Amyloclastic Assay. The substrate
starch is complexed with iodine molecules. The enzyme cleaves the starch releasing the
iodine molecules for a fixed period of time during which time the intensity of the blue
iodine complexes decreases (32). The absorbance can then be directly related to the
starch-iodine calibration curve to estimate the enzyme activity (33).
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However, the convenience of the amyloclastic methods is overshadowed by the lack of
reliability. Also methods incorporating starches labelled with dyes have narrow analytical
ranges and poor correlation with established reference ranges (34).

Nephelometric assays proved to be rapid and simple, however, they posed the problems
of requiring specific instrumentation and the preparation of a stable and reproducible
starch substrate which proved to be an nonfeasible option (35).

Turbidimetric assays proposed however were not widely accepted due to similar
problems as neophelometric assay.

1.7.2

Saccharogenic Assays

In saccharogenic assays, the activity of the enzyme is determined by the quantity of
reducing material produced.

Similar to amyloclastic assays there are several variations

upon this technique.

There are few if any direct saccharogenic assays being universally used. However the
principle is the basis for the development of more popular techniques.

Saccharogenic assays, namely Somogyi-Nelson Method and Folin-Wu Method are still
respected for their accuracy but are now rarely utilised due to their tedious nature and the
difficulty in preparing reproducible substrates (36).
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1.7.3

Chromogenic Assays

There are two types of chromogenic substrates, dye-couple methods and enzyme-couple
procedures. Of these two, the latter is quickly growing in popularity.

The most popular examples of dye-couple methods were Amylochrome (Roche
Diagnostic Systems) and Kodak EKTACHEM amylase slide method (37).

The main

disadvantage of these assays was the degree of manual work which had to be carried out.
Often the substrates, amylose, amylopectin or a defined oligosaccharide plus an indicator
dye was required to be centrifuged or filtered thus proving to be quite time-consuming
(35).
Hence a gap in the market loomed for an easily automated assay using a dye linked to a
substrate resulting in the introduction of an enzyme-coupled procedure.

The

incorporation of auxiliary enzymes into the reaction procedure lead to the immediate
improvement of reaction stoichiometry and more consistent hydrolysis rates.

Kaufman and Tietz (34) were first to propose a kinetic method for measuring enzyme
activity utilising auxiliary enzymes. Their method was based upon the reaction principle
of;
a-amylase
Starch ---------------> Maltose + maltotriose + dextrin

a-glucosidase
Maltose + maltotriose ------------------- > Glucose

Glucose + 1/2 O2

glucose oxidase
______________ > H2O2 + 5-gluconolactone
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The rate of glucose production was determined by the enzyme glucose oxidase (EC
1.1.3.4) and a Clark Oxygen Electrode to measure the decrease in p02. It was defined
that for every mole of glucose oxidised, 0.5 mol of oxygen is consumed. Thus, the rate
of removal of oxygen from solution is directly related to the amylase activity in the
sample.

A modification was made on this procedure to allow the activity to be read
spectrophotometrically, thus improving upon the automation of the technique.
Peroxidase enzyme (EC 1.11.1.7) is added as an indicator reaction using the
diammoniurn salt of 2,2'-azine-di-(3-ethylbenzthiazoline)-6-sulfonic acid (ABTS).

Peroxidase
H2O2 + ABTS (Reduced) -

-> H2O + ABTS (oxdised)

(Colourless)

(Coloured)

The increase in absorbance at 410nm is directly proportional to the enzyme activity.

Further advances in enzyme-coupled reactions incorporated the use of NADH. However
this posed new difficulties to the assay as NADH proved unstable and absorbance
changes were small. These kits are still commercially available;
"Eskalab-Amylase" (Smithkline Instruments) and " a-Amyl-Harleco"
(Harleco NJ) (35).

More recently, maltooligosaccharides of defined chain length have been introduced as
substrates for a-amylase. The exact number of residues of the oligosaccharide involved
has a significant effect on both ;
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(1)

The rate of the hydrolytic degradation.

(2)

The product pattern produced as a result of a-amylase (37).

The shorter the chain length of the oligosaccharide substrate, the more defined and the
greater the stability of the assay. This principle was utilised by the "Enzymatic Amylase
DS" (Beckman Amylase DS Procedure) and the "Aca Amylase" (Du Pont Procedure).

The Beckman Procedure utilises the substrate maltotetrose which immediately improves
upon the sensitivity and linearity of the reaction. It incorporates a complex auxiliary and
indicator enzyme system for measuring the reducing products generated. The reaction is
as follows :

a-amylase
Maltotetrose + H2O------------------------- > 2 maltose

maltose phosphorylase
2 Maltose + 2PO4__________________ > 2 glucose + 2 glucose-1-phosphate

p-phosphorylase
2 glucose-1-phosphate---------------------- > 2 glucose-6-phosphate

G-6-PDH
2 glucose-6-phosphate +2 NADP"^

> 2,6-phosphogluconate
+ 2NADPH + 2H+

However, the main limitation of this assay, is an underestimation of amylase activity due
to the presence of glucose and maltotriose in the mixture. The Du Pont assay utilises the
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substrate maltopentose which is hydrolysed by amylase to give maltose and maltotriose.
This assay offers the advantages of accurate and reproducible results and glucose
interference is minimised by use of a gel filtration column (38).

A significant

disadvantage though is non-linear kinetics displayed by both the reagent blank and patient
samples. Though all of these methods represented significant methodological advances
for the accurate measurement of a-amylase, no one assay as yet could give a simple
direct reading with minimum interferences.

Oligomers with more than six glucose units are hydrolysed more rapidly than shorter
substrates as they resemble the natural a-amylase substrates more closely. So
p-Nitrophenylheptaoside was suggested as a potential substrate by Scholer, A. (39). As
the name suggests, a 4-nitrophenyl moiety was bonded to the reducing end of the seven
residue oligosaccharide. Under optimum conditions, the enzyme a-Amylase hydrolyses
the 4-NP-G7 to release the free chromophore nitrophenol, however this proceeds very
slowly (40). Thus the inclusion of an auxiliary enzyme a-glucosidase into the reaction
mixture was made.

The addition of a-glucosidase has both positive and negative effects.

The obvious

advantage is the more rapid hydrolysis and release of the chromophore 4-NP. However
a-glucosidase can cause the spontaneous hydrolysis at the non-reducing end of the
oligosaccharide.

David determined the kinetic studies of

a-amylase with p-

Nitrophenyloligosaccharides to obtain the maximum rates of reaction by including the
auxiliary enzyme (41). It was observed that much less auxiliary enzyme was required
when using G5 and G6 oligosaccharides. However as it was proven that G7 had a higher
affinity for a-amylases (40), and provided high rates of linear absorbancies. Balancing
these contradictory constraints, 4-NPG7 was found to be the best-suited substrate. It
was then found that a blocking group could be added onto the non-reducing end of the
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substrate (42). This in turn would prevent the slow hydrolysis by a-glucosidase (43).
Commonly used blocking agents include 4,6-ethylidene or 3-ketobutylidene.

The

blocked substrate shows a different and more productive hydrolysis pattern. Principally,
a 4,6-ethylidene blocked NP-Gy produces upon hydrolysis d-NP-Gy (40%), 4-NP-G3
(40%) and 4-NP-G4 (20%) approximately (44).

Therefore the concentration of 4-NP

released is increased. The amylase activity is determined from the direct increase in 4nitrophenol monitored at a wavelength of 405nm (45). However any advantage gained
by an increased production of 4-NP is counterbalanced by an overall degradation of a
blocked substrate by a-amylase and can be described as follows;

a-amylase
Blocked pNP-maltoheptaoside(EPS)---------------------- > bl.-Gy-s + Gy-s-pNP

a-glucosidase
G2-5-pNP--------------- ----------> glucose + pNP-glucoside

a-glucosidase
pNP-glucoside----------------------------> glucose + pNP

Hohenwallner, W. et al. (47) in five different laboratories established working reference
ranges for amylase samples in urine and serum. A good correlation was found between
the blocked pNP-Gy substrate and the pNP substrate.

With further advancement new indicator groups were developed as nitrophenol produced
some limitations. The 4-nitrophenol indicator group has a pKa value very close to that of
the pH of the assay, that is , approximately 7.0. Therefore only about 50% of the 4-NP
formed is spectrophotometrically detected. Also, the salivary isotype appears to display a
greater affinity towards this new substrate (48). Thus the indicator group of 2-Chloro-4-
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nitrophenol was chosen as the basis of a new substrate (49). The main advantages of the
substrate 2-Chloro-4-nitrophenyl-p-D-maltoheptaoside (CNP) are (48);
(1)

Minimum differences between the rates of hydrolysis by
Salivary or Pancreatic Amylases.

(2)

Easily automated.

(3)

CNP has a pKa value of 5.1, so it is fully dissociated at the
assay pH, so up to 70% of products produce a signal.

(4)

Smaller sample volumes are required which improves
sensitivity and precision of the assay.

Increased amount of variations were subsequently proposed. Tokutake, S. et al. (50)
developed a new blocked substrate containing CNP as an aglycone, 2-chloro-4nitrophenyl 4'^-0-[3-D-galctopyranosyl-b-maltopentaoside.

Two products, 2-clTJoro-4-

nitrophenyl-P-maltoside (PCNP2) and 4'^-0-P-D-galactopyranosyl-maltose (Gal-G2)
account for more than 99% of the products generated from Gal-CNPG4 by human
salivary and pancreatic a-amylase, both of which can be further hydrolysed by the
auxiliary enzymes a- and P-glucosidases (51).

A further addition to the growing number of methods for determining amylase activity is
the use of the substrate 3-ketobutylidene p-2-chloro-4-nitrophenyl-maltopentaoside.
This method provides all of the above mentioned advantages of using CNP linked
substrate. The blocking agent 3-ketobutylidene providing sensitivity and stability to the
assay (52).

However all of the above chromogenic assays require the presence of

auxiliary or indicator enzymes. Winn-Deen et al. (53) were among the first to attempt to
develop a direct colorimetric assay, in which a-amylase could directly hydrolyse the
substrate yielding a colour change. The lack of presence of auxiliary enzymes has three
major effects upon the reaction:
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(1)

Eliminate the requirement of a lag phase.

(2)

Improve the stability of the substrate.

(3)

Dismisses the requirement of a blocking agent.

The reaction rate is based upon ;

5CNP-G3

a-amylase
------------------ >3CNP + 2 CNP-G2 + 3 maltotriose + 2 glucose

The enzyme directly cleaves a free chromophore and the lack of a blocking agent at the
non-reducing end of the molecule dismisses the requirement of auxiliary enzymes.

While recent research has made a remarkable improvement on the Amylase assay for the
development of a selective, sensitive, stable and rapid assay. It has also caused a wide
interlaboratory distribution of methods for serum a-amylase activity determination.
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1.8

Amylase Isoenzyme Determination

As mentioned previously, serum a-amylase is a heterogeneous enzyme existing in two
principle forms ; Salivary and Pancreatic. The former isotype is not tissue specific. It is
synthesised by salivary and sweat glands, lung, bronchogenic and ovarian tumours.
Pancreatic amylase is almost fully tissue specific being found in semen also. Therefore a
hyperamylasemia case may not always signify pancreatic disorder, but may be a signal of
cases such as mumps, intestinal disorders or tumours depending upon which isoenzyme is
elevated. Hence for clinical situations, the need of a simple, rapid, selective and sensitive
test is required to determine the isoenzyme activities.

Several methods have been developed for isoenzyme determination. These include :

1.8.1
In

(1)

Electrophoresis

(2)

Iso-electric focusing

(3)

Ion-exchange chromatography

(4)

Immunoinhibition

(5)

Selective Inhibition

Electrophoresis

1964,

isoenzymic forms of amylase were successfully separated (54) by

electrophoresis. A wide range of supporting media have been developed to fully optimise
electrophoretic mobilities. These include polyacrylamide, cellulose acetate and agarose.
With each new supporting medium, buffers, ionic strength, pH, voltage and running time
have to be modified. With increasing improvements the resolution has been sharpened,
highlighting the presence of minor bands in both isoenzymes, representing isoforms of
both salivary and pancreatic amylase.

1

As discussed previously these minor

..
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heterogeneous bands are derived from post-translational modifications.

Once the

electrophoresis run is over, a staining step is required to visualise the bands.

In 1979, Gillard, B.K. (55) described a simple direct procedure for quantitatively
determining the S / P ratio for normal or below-normal total serum amylase.

The

amylase isoenzymes are separated into the two principle isotypes by electrophoresis in a
polyacrylamide gel. The enzyme activity is measured directly in the gel by incubating
them in soluble-starch solution, staining with iodine and densitometry. Amylase bands
were revealed as clear zones of degraded starch against a dark background of iodinestained starch (56). This is a very sensitive and precise method allowing the separation of
the two major isoenzymes. However it's application to clinical laboratories for routine
use is limited, due to the lengthy incubation periods required for both the electrophoresis
and the reaction with the Starch;Iodine complex.

Some primary disadvantages of using polyacrylamide as a support media despite it's
excellent resolution, is the fact that in it's unpolymerised state, acrylamide is toxic and it's
conversion to the polymerised form can be unpredictable (57).

Improvements were made by varying the type of gel from polyacrylamide to agarose.
From this change it was possible to resolve the salivary and pancreatic amylase into both
major and minor constituents owing to post-translational modification (58). This method
proved to be extremely sensitive, detecting pancreatic and salivary amylase samples with
activities as low as 30 U/L using Phadebas Amylase Test tablets.
amylase isoenzymes separated from cathode to anode as follows (59):
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It was found that

©
S4
S3
S2
S1
P3
P2
P1

0
Figure 3:

Electrophoretic illustration of amylase from various sources;
1 - Pancreatic extract 2 - Salivary extract

3 - Acute pancreatitis

4 - Mumps.

Electrophoretic separation of amylases through agarose is difficult due to the enzymes
affinity for the agarose as a potential substrate. Therefore for improved resolution an
increase in the running time is required.

Massey improved upon the efficiency of the electrophoretic technique by substituting the
agarose gel with cellulose acetate (60). This technique has now been advocated as the
routine assay of serum isoenzymes. Massey improved the technique by focusing on the
problems highlighted by Frost (61). Here he reported the P3 band migrated very closely
to the major S band and so it proved difficult to interpret. The P3 band was found to
appear only in patients with acute pancreatitis or renal failure. So it became imperative
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to try and resolve clearer and more distinctive P3 and major S-type bands.

Massey

named the region between the P3 band and the slightly faster migrating SI band as P'.
Quantification of the P3 component of P' required careful measurement of migration
distances of P' and P2 thereby deriving a P3 index. It was discovered that by the addition
of CaCli into the electrophoresis buffer, P3 and SI bands were completely resolved.
Thus providing an easy and effective method of determining a-amylase isoenzyme
activities. Overall the cellulose acetate proved easy to process and scan, however some
resolution was lost to that of agarose or acrylamide.

The main advantages of electrophoretic amylase isoenzyme determinations lie in speed,
simplicity, and small sample volume requirements. It is capable of resolving amylases
that are not readily resolvable via ion-exchange chromatography for example the
appearance of P3 band in acute pancreatitis. Under clinical application, it qualitatively
reveals the presence of the specific isoenzymes and isoforms.

1.8.2

Iso-Electric Focusing

Electrophoresis depends primarily upon the charge carried by a molecule but at it's iso
electric pH (pi) a molecule will not migrate in an electric field. This was the theory
applied to the technique of separating the two major bands of amylase. Takeuchi, T. et
al. developed and optimised successfully the principle of the experiment and managed to
separate salivary amylase from pancreatic amylase (62).

Electrofocusing had the advantage of giving higher resolution and better separation of
isoenzymes than electrophoresis, however the time scale was totally inconvenient with
regards to emergency or even practical diagnostic cases. The whole procedure took in
excess of sixty hours to run. So, this left the market open for a more convenient method
of isoenzyme differentiation.
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1.8.3

Ion-Exchange Chromatography

Chromatography based upon the principle of molecular sieving is not applicable to the
case of separating both the isoenzymes and isoforms of amylase due to the similarity in
their molecular mass. A more favourable method is using their difference in net electrical
charge to separate the pancreatic and salivary isoenyzmes.

Ion-exchange chromatography on gels of DEAE-Sephadex is the most commonly used
column chromatographic technique for isoenzyme separation but DEAE-Cellulose and
QAE-Sephadex have also been used. At pH > 8.0, the amylases have an overall negative
charge and therefore bind to the positively charged column dextran molecules. Salivary
amylase however is slightly more negatively charged and so binds more effectively and is
therefore eluted last (63). Thus providing a distinct separation of the two isoenzymes.

As previously mentioned serous ovarian tumours contain a high level of amylase activity
which was found to be " an acidic amylase" (30).

The acidic nature of this amylase

provides the key in detecting it's presence in samples.

Upon lowering the pH in the

DEAE-Sephadex column from 8.0 to 7.15, both salivary and pancreatic isoenzymes co
elute in the void volume. However the ovarian tumour amylase remains firmly bound to
the column.

Zakowski et al. developed the method to detect the acidic amylase as it

provides a useful marker for the most common type of ovarian cancer (30).

Ion-exchange column chromatography for the separation of amylase isoenzymes has
several advantages. Firstly it provides a simple and usually effective separation of the
isoenzymes. Recoveries are high and the relative proportions of the isoenzymes can be
readily determined by assay of the eluted fractions. Modification of the procedures has
allowed the development of mini-columns which improves the sample volumes viability.
Sample volumes have been decreased from 10ml to <lml, with the procedure taking a
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matter of hours. The high capacity and economy of the technique is somewhat marred by
the sensitivity of the procedure.

Buffer concentration, ionic-strength and pH are all

critical for correct separation and therefore must be carefully monitored (64). This rules
out it's potential use in emergency cases but ion-exchange column chromatography
remains a useful tool in research laboratories.
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1.8.4

Immunoinhibiton

Seeking a more convenient assay for the measurement of a-amylase isoenzymes, the
primary structure’s of the two principle isotypes were examined. It was discovered that
the principal differences between the two isoenzymes occur in the glycosylated region of
the enzymes (65).

Recent cDNA studies of the two isoenzymes revealed a 93%

sequence homology (66).

It was therefore concluded that there should be slightly

different immunological responses by both S- and P-type amylases (67) . Basing the
principle of the assay on expected antigenic responses, polyclonal antisera were
developed.

However cross-reactivity occurred between the pancreatic and salivary

amylases because of their homology (68).

As mentioned previously, pancreatic amylase determinations have proven to be slightly
more specific and informative on the identification of the onset of acute pancreatitis and
macroamylasemia than total amylase determinations.

Therefore, more recently, the

search was begun for a monclonal antibody which specifically recognised salivary
amylase isoenzyme.

Mifflin et al. were among the first to isolate and produce this

selective monoclonal antibody (69).

The assay is based on quantitatively removing

salivary amylase from serum by binding to the monclonal antibody which is immobilised
onto a solid phase support.
measured.

This allows the free pancreatic amylase activity to be

Further modifications have been made by both directly and indirectly

immobilising the enzyme to the antibody (68).

Up to now, salivary a-amylase specific monoclonal antibodies only allow the
determination of isoamylase by a separation step using immobilised antibodies bound to a
paper support or microtitre plates (67). Gerber et al.. developed a monclonal antibody
88ES which specifically bound and inhibited human salivary a-amylase (70).

The

antibody which has an IgG subtype 2a included completely binds to SI and S2 isoforms
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overall inhibiting pure human S-type amylase by 91%. It produces a mixed-type non
competitive inhibition by having the ability to bind either free enzyme or the enzymesubstrate complex.

Follow up work on the evaluation of these double monoclonal-antibody techniques was
carried out. (70, 72)

With regards to speed, precision, accuracy and specificity it is

superior to other techniques of amylase isoenzyme differentiation and is more useful for
the clinical routine and emergency laboratory by excluding false-positive amylase
elevations due to non-pancreatic diseases (73).
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1.8.5
The

Selective Inhibition
previous

methods

up

to

now;

electrophoresis,

iso-electric

focusing

and

chromatography have successfully managed to separate the two isoenzymes of amylase
but involve tedious and time-consuming techniques. For clinical applications, a simple
rapid and reliable method is most desirable.

Some of the more recent advances has

involved the use of amylase inhibitors that are relatively specific for either the salivary- or
the pancreatic-isoenzyme.

A protein inhibitor of the a-amylase enzyme was first described in the 1940's from a
wheat seed. But it wasn't until 1976 that O'Donnell and McGeeney pursued studies on
the wheat-germ seed inhibitor (WGI) to investigate if selective inhibition actually
occurred (74). They discovered through inhibition curves that the inhibitor displayed a
much greater specificity towards salivary amylase than towards the pancreatic isoenzyme.
It was found that 90% of the salivary enzyme was inhibited while only 20% of the
pancreatic-type was inhibited (75). This initial work proved that with inclusion of the
inhibitor with a patient sample analysis of salivary / pancreatic ratios could be observed.

On analysis of the wheat seed {Triticum aestivum ) a-amylase inhibitor, three different
proteins in the 20 - 25,000D Mr range were isolated all with greater specificity for human
salivary amylase. Type II WGI appeared to be more than six times more effective an
inhibitor of human salivary amylase than Type I and more than an order of magnitude
more specific for S. Amylase relative to P.Amylase than Type III (76).

Goff et al.

studied the mode of inhibition and found the formation of the a-amylase : inhibitor
complex was best achieved by allowing the enzyme and inhibitor to pre-incubate for
more than 25 minutes @ 20_C preceding addition of the substrate. A lag phase of 15
minutes was then necessary to establish a steady-state among free enzyme, enzyme ;
inhibitor complex and enzyme ; substrate complex with the latter leading to product. The
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WGI was found to exhibit competitive inhibition characteristics (77).

O'Donnell and

McGeeney developed the differential serum amylase assay combining the use of the WGI
and typical saccharogenic assays.

Huang et al. (78) in 1982, saw that the main

disadvantage of the method was the labour intensive step of a 25 minute preincubation of
E + I, proceeded by a 15 minute step of substrate with sample and subsequent
centrifugation steps before a photometric result.

This was around the same period of time when chromogenic substrates were in the
process of being developed for total amylase assays. This led to the development of the
combination of inhibitor with commercially available chromogenic substrates, for
example, Beckman Enzymatic Amyalse - DS procedure.

The improvements were

dramatic. The preincubation step decreased from 25 to 5 minutes and the assay volumes
dropped, automatically making the whole procedure more viable. The assay lent itself to
being easily automated. The optimum inhibitor concentration decreased considerably by
about 12% to achieve inhibition rates of 88% against S.Amylase and 19% against
P. Amylase.

The ratio of the inhibited activity to the total uninhibited activity is then

plotted on a standard curve to determine the relative percentages of the P- and Sisoenzymes (79).

However, the main drawback was the isolation and purification steps for obtaining the
WGI, involving fractionation, ion-exchange chromatography, and gel-filtration.

So, in

1984, when the wheat germ inhibitor became commercially available it became far more
feasible for use in clinical diagnosis both routinely and in emergencies (80).

With further technological and scientific advances, chromogenic substrates which could
give direct readings with minimum interference’s were developed and became
:ommercially available.

As previously mentioned oligosaccharides with 4-nitrophenyl
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moiety attached to the reducing end of the substrate became universally accepted.
Various experiments and trials were carried out using oligosaccharides of varying lengths
(81). However, it was discovered that not all oligosaccharides could be used in these
specific inhibition studies. Some substrates have products which have the potential to be
inhibitors thereby resulting in feedback inhibition of the reaction (82).

Further investigative studies were done to try and improve the inhibition levels on the
isoenzyme of choice. Courtois and Franckson attempted to achieve 100% inhibition of
S.Amylase and 50% inhibition of P.Amylase with the now widely accepted selective WGI
(83). The use of a two-step procedure to determine total activity of one aliquot and the
residual activity after inhibition in a second aliquot which was by now universally
accepted was repeated.

A ratio of 1 / 1 (v ; v)

of sample and inhibitor was used.

However to achieve the required new inhibition levels, a one hour preincubation step was
used. This of course while suggesting the fact that a standard curve was not needed,
ruled out it's use as an emergency procedure. Further work involved reverting back to
previously accepted assays and optimising these assays for automated centrifugal
analysers using 4-NP-G7 as substrate (84, 85). The assays proved precise, rapid, linear
inhibition curve kinetics and good correlation was found between these assays and other
methods e.g. Phadebas Kinetic Amylase and Kinetic Amylase Inhibitor (KAI).

Substrates such as 3-Ketobutylidene-p-2-chloro-4-nitrophenyl maltopentaoside
(3KB-G5-CNP) were also evaluated in a double kinetic assay for determining total and
P. Amylase with use of the WGI in a single channel on an automated analyser.

The

substrate which is blocked by 3 KB at the non-reducing end is unaffected by auxiliary
enzymes as required.

Total amylase was measured in the first analytical process and

P.Amylase was measured in the second after an inhibitor of S.Amylase was added. The
sensitivity of this particular method surpassed the EPS method, as the products produced
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from the blocked end of the substrate were degraded immediately.

It provided the

advantage over the monoclonal antibody method by allowing the simultaneous
determination of the second isoenzyme. Thus allowing the multiple information on T.-,
S.- or P.-Amylase activities to aid in the diagnosis and treatment of the diseases (86).

Cereal proteins are of increasing clinical interest due to the presence of protein inliibitors
and proteases. a-Amylase inhibitors have been found in Rye (87), Kidney Beans (88,
89), Sorghum (90) and Oat endosperm (91).

Their use in the clinical analysis of the

differential activity of amylase isoenzymes is limited, due to the lack of total specificity
towards just one isotype.

In 1995, a new differential assay was developed which

reported that deoxymaltooligosaccharides with a 6-deoxy-D-glycosyl group at the non
reducing end were potent selective inhibitors of human pancreatic amylase.

6^-

deoxymaltotriose (DOGS) demonstrated a significant inhibitory difference between S.and P.-Amylase (92). Uchida, R. et al. proposed the use of a new synthetic chromogenic
substrate 2-chloro-4-nitrophenyl-6^-azido-6^-deoxy-P-maltopentaoside (N3G5CNP) for
both a single kinetic and a double kinetic assay with DOGS as the selective inhibitor. The
reaction principle is as follows:

a-amylase
NSG5CNP--------------------- > NSGS + G2CNP

glucoamylase
G2CNP---------------------------- > 2G + CNP
p-glucosidase

The mode of inhibition with DOGS is competitive (9S).

Under fully optimised

conditions, DOGS displayed a large inhibitory difference between human P.Amylase
(86.9% inhibition) and S.Amylase (S2.1% inhibition). So, while the assay proved easily

S2

automated, rapid, with a short preincubation period (2 mins, versus 5 mins, in the WGI
assay) and linear kinetics, the inhibitor DOGS lacked complete specificity. Upon direct
comparison the WGI displayed a superior inhibitory difference towards the Amylase
isoenzymes.

With this background knowledge of a-Amylase and it’s isoenzymes, the emphasis was to
study the clinical significance of the enzyme. Emergency patients with suspect symptoms
of acute pancreatitis could be quickly diagnosed if a routine clinical assay was
commercially available. From the literature review, it was clear that there were a number
of possible techniques to differentially measure the two isoenzymes, however time was
oflen a deciding factor. The most likely method was by selective inhibition. Through
research it was discovered that there were a number of different protein inhibitors
available which had the inhibition properties necessary for the assay. But the degree of
selectivity and specificity was in doubt.

Two principle inhibitors were tested in the

course of this research, the wheat germ seed from Triticum aestivum and the synthetic
inhibitor DOG3.

1.9

Summary

The objectives of this project were;
•

To develop and optimise an assay to selectively measure the individual isoenzymes of
a-Amylase by selective inhibition.

•

Automation of the assay.

•

Test it’s efficiency with modem blocked oligosaccharide chromogenic substrates.
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2.1

Materials

2.1.1

Apparatus

Shimadzu UV - 160A.
Was used initially during the project to measure absorbance values. Once
kinetics of the assay were established an automated centrifligal analyzer was
used.

CentrifiChem System 500 - Baker Instruments.
This centrifugal analyzer is a precision instrument which performs
spectrophotometric analysis of standard, control and serum samples. It is
possible to program the analyzer for specific reaction conditions such as lag

time, reaction time, wavelength and temperature. The analyzer operates by a
centrifligal technique which forces the samples and reagents to mix for the
pre-set length of time. The resulting changes in absorbancies are printed
automatically.

CERES 900C EIA Scanning Autoreader and Micro plate Workstation Bio-Tek Instruments, Inc., Vermont, USA.
The CERES 900C is an integrated reader - assay management system designed
to automatically perform complete kinetic, end-point and scanning analysis.
The CERES 900C includes the features ;
*

96 - well micro plate carrier.
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*

Incubator voltage selector switch, capable of incubating plate up to
50OC.

*

Plate shaker switch of varying intensity.

*

Kinetic and endpoint curvilinear regressional and statistical
calculations.

*

Programmable assay parameters such as wavelength, lag phase and
reaction time.

*

Results of 96 - wells displayed in the form of graphs or absorbance
values.

4.

Microtittre Plates.
Nunc - Immuno Plate, MaxiSorp.

5.

CentrifiChem Pipettor 1000 - Baker Instruments.
The pipettor is automated to deliver pre-programmed microlitre quantities of
blanks, standards, controls and serum samples with reagents into separated
compartments in a transfer disc. Up to and including four different reagents may
be dispensed into the transfer disc.The transfer disc is then sealed in the
centrifugal analyzer's chamber and the rotor spin cycle is started. A maximum
of 29 samples can be included in a transfer disc.

6.

pH Meter.
Orion - bench top pH/ISE meter, model 420A is a microprocessor controlled
instrument which features pH auto calibration.
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7.

Millipore Water Purification System.
The Millipore - milli - ulO purification system produces Grade 2 (according to
ISO 3696 / B53978) purified water directly from deionisation using a mixed
bed ion-exchange resin. The resulting product water is low in inorganic ions,
dissolved organic compounds, bacteria and colloidal matter.

8.

Incubator.
Gallenkamp Size 3 incubator - Model IH-100 was used to keep samples at a
constant temperature of 37<^C.

9.

Uvikon 930 - Kontron Instruments.
A water-bath linked temperature controlled spectrophotometer. Capable of
recording absorbance values under defined set of assay parameters.
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2.1.2

Chemicals

All chemicals and reagents used throughout this project were obtained (unless otherwise
stated) from ;
Sigma Chemical Company.
Fancy Road,
Poole, Dorset,
BH 17, 7 NH, England.

Salivary a-Amylase from Human Saliva, 10^ I.U./L.
Pancreatic a-Amylase from Human Pancreas obtained from Biogenesis Ltd.,
Poole, England.
a-Amylase Inhibitor from Triticum aestivum Type I.
a-Ajnylase Inhibitor from Triticum aestivum Type II.
a-Amylase Inhibitor from Triticum aestivum Type III.
a-Amylase CT Kit obtained from Human Diagnostica .
a-Amylase Liquicolor Kit obtained from Human Diagnostica.
Control Serodos Plus Serum obtained from Human Diagnostica.
Amyloglucosidase.
p-Glucosidase.
* 6'^ - deoxymaltotriose.
* 2-chloro-4-nitrophenyl-6^-azido-6^-deoxy - (3 -maltopentaoside.
* Both kindly donated by R. Uchida, Kikkoman Corp., Japan.
P-Amylase Monoclonal Antibody Kit obtained from Boehringer Mannheim
Diagnostics and Biochemicals, UK.
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2.1.3

Buffers

The following buffers were used throughout the course of this project ;

Phosphate Buffer, pH 6.9.
Containing 0.015M Na2HP04, 0.03M KH2PO4, 50 mM NaCl, 0.5 mM CaCb.

CaCb, ImM used to reconstitute Salivary Amylase.

CaCb, 0.5 mM used to reconstitiute Salivary Amylase.

Rla:

R3a:

R3b:

EPS Substrate:

HEPES buffer, pH 7.2

100 mM

CaCl2

1.5 mM

NaCl

75 mM

Amyloglucosidase

75 kU/L

P-Glucosidase

7.5 kU/L

Citric Acid

2mM

N3G5CNP

6.1 mM

Citric Acid

2mM

N3G5‘CNP

6.1 mM

DOG3

1 mM

PIPES Buffer, pH 7.3

48.6 mM

CaCl2

2.52 mM

NaQfe .

48.6 mM

,

EPS

2.5 mM

a-glucosidase

>27 kU/L
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CNPG3 Substrate:

MES Buffer, pH6.0

36.1 mM

CNPG3

1.63 mM

Calcium acetate

3.6 mM

NaCl

37.2 mM

Potassium Thiocyanate

253 mM

NaNs

0.095%

a-glucosidase

>23 U/mL

Monoclonal Antibodies

35 mg/mL

HEPES Buffer, pH7.1

100 mM

NaCl

50 mM

MgC12

lOmM

EPS

3 mM

Boehringer Mannheim Kit
Concentration in the Test:
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2.2

Methods

The original assay for measuring total serum amylase from which all of this work was
derived was obtained from O'Donnell and M^Geeney. From this and other papers the
assay was consistently modified.

2.2.1

O’Donnell and M^Geeney Method for Total Amylase.

The substrate originally used in this method was insoluble starch.

However it was

realized that salivary and pancreatic amylase both hydrolyse the substrate at different
rates. The first modification on this method was replacing the original substrate with a
new

chromogenic

substrate,

namely

4,6-Ethylidene(G7)-p-nitrophenyl-(Gi)-a-D-

maltoheptaoside (EPS).

The terminal glucose residue is bonded to a blocking agent to prevent cleavage by the
auxiliary enzymes present and to enhance the stability of the reagent.

a-amylase
Blocked EPS ----------------------------- > bl.- G2-5 + G2-5 - pNP

a-glucosidase
G2-5-PNP ------------------ -------------> Glucose + pNP-glucoside

a-glucosidase
pNP-glucoside --------------------------> Glucose + pNP

The ultimate release of the chromophore p-nitrophenol (pNP)

causes an increase in

absorbance per minute at 405nm which is directly related to the activity of the enzyme a
-amylase.
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The original assay by O’Donnell & McGeeney was developed as a manual assay.
Therefore pipetting parameters had to be adjusted and optimised for use as an automated
assay. The total volume was determined by the limit of the Centrifichem’s fill volume.
The sample : substrate ratio was tested throughout a range and was found to produce
optimal results at 1 ; 50. Reaction times and lag phases were determined by the substrate
EPS.

Both were significantly reduced due to the change from the original substrate,

Phadebas Cibachron Blue Starch used by O’Donnell & McGeeney.

(i)

0.3mL

Phosphate Buffer (pH 6.9, 50mM)
containing 50mM NaCl, 0.5mMCaC12

(ii)

0.2mL

Sample

Mixture was gently mixed and allowed to preincubate at room temperature
(20°C) for 25 mins. The solution was diluted to a volume of 4. ImLs with dH20.
7ml of this mixture was combined with the substrate and diluent for the reaction.

Assay Parameters
CentrifiChem Parameters

Pipettor Parameters
Substrate
Sample
Diluent

350ul
7ui
15ul

Filter
Time Interval

405nm
15s

Temp
Lag Phase

37®C
5min

Blank Auto
Test Mode

Auto
Rate

Rxn Time

3min

Print Out
Cone. Factor

Abs.
0000

No.of Prints

1

A diluent (dH20) is added to the reaction to aid the mixing of the E
dAbs./min. was calculated and the activity of the enzyme is estimated.
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and S.

2.2.2

O'Donnell and McGeeney Method for Isoenzyme Determination.

The introduction of a selective Amylase Isoenzyme inhibitor into the O’Donnell and
McGeeney assay brought about the possibility of identifying the isoenzyme ratio in serum
of patients with suspected cases of pancreatitis.

The wheat germ seed inhibitor from

Triticum aestivum was introduced into the new optimised O’Donnell and McGeeney
assay as described in method 2.2.1. The sample : inhibitor volume ratio was optimized to
be 20 ; 1. The concentration of Inhibitor jug/pL was varied to find the optimum effective
inhibition concentration. The inhibitor concentration ranged from
0-----> 0.136pg/pL.

(i)

Phosphate Buffer

30pL

(ii)

Sample

20pL

(iii)

Inhibitor

IpL

Preincubate for 25 mins, at R.T.
Dilute to a volume of 410pL with dH20.
The final assay pipettor parameters were as per method 2.2.1., whereupon 7pL of
the mixed solution was taken and allowed to incubate with substrate and diluent
for a 5 minute lag phase before the assay was begun.
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2.2.3

Huang and Tietz Method for Total Amylase Determination.

The original Huang & Tietz method offered immediate advantages over the O’Donnell and
McGeeney Assay (Method 2.2.1). It differed by the following;
(1)

Smaller reagent volumes.

(2)

Smaller E : S ratios.

(3)

Shorter inhibitor and enzyme preincubation times, therefore increasing the

potential use for emergency cases.
The method was optimized for it’s use on the Centrifichem Analyzer and the incorporation
of the substrate EPS, in place of the maltotetrose substrate of the original method.
Similarly to the adaptations imposed upon the O’Donnell and McGeeney Method, reagent
volumes were limited due to the holding capacity of the Centrifichem

Assay Parameters
Centrifichem Parameters

Pipettor Parameters
Substrate
Sample
Diluent

310ul
20ul
80ul

Filter
Time Interval
Blank Auto
Test Mode
Print Out
Cone. Factor

405nm
30s
Auto
Rate
Abs.
0000

No.of Prints

1

Temp
Lag Phase
Rxn Time

37®C
5min
3min

It should be noted that a modification introduced by the author to the Huang &
Tietz Method required that the E and S be preincubated seperately @ 37°C for
5mins.
Also note that a similar modification was introduced into the O’Donnell &
McGeeney protocol which required that the sample and buffer be preincubated
after mixing for 25mins @ 20°C.
This proves to be a simpler and more rapid method over the ODonnell and
McGeeney Method for measuring the activity of amylase.
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2.2.4

Huang and Tietz Method for Isoenzyme Determination.

As mentioned in section 2.1, the pipettor is capable of delivering up to and including four
different reagents into the transfer disc. Therefore pipettor parameters are adjusted for the
newly modified Huang &Tietz Method accordingly to incorporate the addition of the
Wheat Germ Inhibitor.

Modified Method
Substrate

310|iL

Sample

20 pL

Inhibitor

20 pL

Diluent

60 pL

The Enzyme and Inhibitor are preincubated together for 5 mins, at 37°C.
A lag phase of 5 minutes is allowed to introduce the substrate EPS into the
reaction.
A range of Inhibitor concentrations (pg/ pL) were examined for inhibition
properties against both S.Amylase and P.Amylase.
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2.2.5

Huang and Tietz Method - Adapted for the CERES 900C Plate
Reader - for Isoenzyme Determination.

At a certain stage in the project, the Centrifichem Analyzer malfuctioned, so during this
period an alternative instrument was used, the CERES 900C Plate Reader. Manual
pipetting techniques were used to transfer the solutions to the microtiter plate. Assay
parameters for the measurement of Total Amylase Isoenzymes (method 2.2.4) were
adjusted accordingly to lie within the specifications of the plate reader.

Assay Parameters

Pipettor Parameters
Substrate
Sample
Inhibitor
Diluent

155ul
10ul
10ul
30ul

Plate Reader Parameters
Filter
405nm
Temp
37"C
Lag Phase 5min
Rxn Time
3m in

Shaking Intensity
Print Out
Cone. Factor
Test Mode

3
Abs.
0000
Rate

Inhibitor concentration 0.018 pg/pL was preincubated with the enzyme in a Nunc
microtiter plate for 5 mins. @ 37^0.
The substrate was brought up to the desired reaction temperature in a
Gallenkamp Incubator.
After a minimum of 300 sec, the substrate was added to the required wells and
gently mixed.
Throughout the duration of the reaction the plate was agitated at an intensity
of 3 (maximum - 5).
Results were displayed in both graphic and absorbance values.
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2.2.6

Wiiin-Deeii, David et aL Method for Total Amylase Determination.

Their method describes a direct colorimetric assay for a-amylase using 2-chloro-4nitrophenyl-a-maltotrioside (CNPG3) as substrate. This assay differs from the EPS
assay due to the lack of auxiliary enzymes in the reaction, therefore no blocking agent is
required and the stability of the reagents is improved. The reaction time is decreased by
the elimination of the lag phase. The overall reaction is based upon;

a-amylase
-> 3CNP + 2CNP-G2

5 CNPG3

+ 3 maltotriose + 2 glucose

The reaction yields a free chromophore, 2-chloro-4-nitrophenol (CNP) from the substrate
and the resulting absorbance increase per minute is directly related to the
a-amylase activity in the sample.

The original paper recommends an sample : substrate ratio of 1 ; 60 by volume, however
the pack insert with this kit provided by Human Diagnostica required a ratio of 1 ; 100.

It was found that on an automated centrifugal analzyer a working ratio of 1 : 40
produced a linear relationship.

The composition of substrate CNPG3 is given in section 2.1.3.

46

Assay Parameters

CentrifiChem Parameters

Pipettor Parameters
Substrate
Sample
Diluent

320ul
Sul
Sul

Filter

405nm

Time Interval
Blank Auto

1 5s
Auto

Test Mode
Print Out
Cone. Factor
No.of Prints

Rate
Abs.
0000
1

Temp
Lag Phase
Rxn Time

37®C
60s
3min

The diluent (dH20) is mixed with the sample to ensure thorough mixing with the
substrate when the reaction is begun.
The Enzyme and Substrate were preincubated independently for a minimum of
5 mins at 37^C.
The results were produced in the form of Absorbance so the activity of
Amylase was calculated accordingly.
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2.2.7

Direct Colorimetric Assay - Isoenzyme Analysis.

For the analysis of the isoenzyme ratio the Winn-Deen et al. method (2.2.6) is modified
to incorporate the selective inhibitor. The inhibitor replaced the diluent volume in this
differentiating assay. The WGI Type II was tried at varying concentrations (}ig/}iL). It
was essential to allow the inhibitor and enzyme to preincubate for 5 mins. A lag phase of
60 sec preceded the reaction run of 3 mins.

Differentating Assay Parameters
Substrate

320}j.l

Sample

8pl

Inhibitor

Spl

The remaining total activity % was estimated by the formula ;

Activity of Inhibited Amylase
Activity of Total Amylase
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X

100%

2.2.8

Uchida, R. et al Method for Total Amylase Determination.

This assay is based upon using a new substrate 2-chloro-4-nitrophenyI-6^-azido-6^deoxy - p maltopentaoside (N3G5CNP).

It requires the presence of two auxiliary

enzymes P-Glucosidase and glucoamylase.

The substrate is cleaved by a-amylase

liberating a free chromophore CNP which is directly proportional to the amount of aamylase present. The reaction system of the method is as follows :

a~amylase
N3G5CNP

-> N3G3 + G2CNP

glucoamylase
G2CNP---------------------------------- > 2G + CNP
P-glucosidase

Assay Parameters
Pipettor Parameters
Sample
Rla
R3a

4ul
200ul
lOOul

CentrifiChem Parameters
Filter
Time Interval
Blank Auto
Test Mode
Print Out
Cone. Factor
No.of Prints

405nm
30s
Auto
Rate
Abs.
0000
1

Temp
Lag Phase
Rxn Time

37®C
1 20s
3min

The sample and Rla (diluent and auxiliary enzymes) are mixed and preincubated
for 5 mins at 37®C.
R3a (substrate) is also brought up to reaction temperature.
Linearity of the continuous measurement was examined.
Composition and concentration of Rla and R3a are in section 2.1.3.
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2.2.9

Uchida, R. et al. Method for Isoenzyme Determination.

The assay parameters were identical to those of method 2.2.8, however reagent R3a is
replaced with reagent R3b which contains the inhibitor DOG3 to develop a differential
assay to measure Amylase isoenzymes.

The Inhibitor and Enzyme are preincubated for 5 mins during which time the inhibitor
acting as a competitive inhibitor binds to the enzyme in a manner which prevents the
substrate N3G5CNP binding.

A lag phase of 2 mins is recommended and the reaction rate is 3 mins.
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2.2.10 Monoclonal Antibody Assay to Specifically Determine the
Pancreatic Isoenzyme.
The reagents were obtained from Boehringer-Mannheim, containing the monoclonal
antibodies. In the first incubation step, the activity of human salivary a-amylase is
inhibited by two different monoclonal antibodies wliich do not affect pancreatic amylase.

After a second incubation with the substrate 4,6-ethylidene(G7)-p-nitrophenyl(Gi)-a-Dmaltoheptaoside, the activity of pancreatic a-amylase is measured.

P-Amylase
5 Ethylidene-Gv-pNP + 5H2O--------------------- > 2 ethylidene-G5 + 2G2 pNP
+ 2 ethylidene-G4 + 2G3 pNP + ethylidene-G3 + G4 pNP

a-glucosidase
2 G2pNP + 2 G3 pNP + IOH2O —--------------------- > 4 pNP + 10 G

For the assay to be carried out on the automated analzyer, the volumes recommended by
the assay kit are adequately adjusted but the ratios are retained.

The composition and concentration of the reagents of the kit are specified in section
2.1.3.
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Assay Parameters

CentrifiChem Parameters

Pipettor Parameters
Enz/Ab.
Sample

250ul
12.5ul

Filter
Time Interval

405nm
30s

Temp
Lag Phase

37®C
3min

Substrate

25ul

Blank Auto
Test Mode
Print Out
Cone. Factor
No.of Prints

Auto
Rate
Abs.
0000
1

Rxn Time

3min

The enzyme / antibody solution and sample are mixed and preincubated for 3
mins at assay temperature.
The substrate solution was also brought up to the desired assay temperature.
The assay was started and lag phase of 3 mins was allowed before the
absorbances were taken.
The mean absorbance change per minute was determined and the activity of the
pancreatic amylase was calculated.
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3.1

Assay 1:

Optimisation of the Method of O’Donnell & McGeeney on the
CentrifiChem® Analyser, using the substrate EPS and Salivary
Amylase.

The original O’Donnell & McGeeney Method was altered and optimised as specified in
Method 2.2.1 to accommodate an automated assay. The overall reaction time decreased
by 8 mins, as a result of incorporating the new substrate EPS.

The stock S.Amylase

enzyme (10^ I.U./L) was reconstituted with dH20 to a concentration of 1 I.U./pL From
this stock a 1/180 dilution of the stock enzyme was carried out to produce a working
concentration of 1 I.U./180 pL, of which 200 pL was added to the Phosphate Buffer for
25 mins, incubation (2) RT.

Table 1. Absorbance values of S. Amylase activiU'
with EPS Substrate of concentration 2.5 mmol/L.

Time (sec)

Absorbance
@ 405nm

0

0.144

30

0.245

60

0.354

90

0.466

120

0.577

150

0.687

180

0.795
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Kinetics of Substrate EPS on S.Amylase.

Graph 1; Linear Kinetics of the substrat^%PS with the isoenzyme Salivary Amylase.
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3.2

Assay 2:

Study the effect of the W.G.I. Type II on Salivary Amylase
using the O’Donnell & McGeeney Method.

To achieve the optimum inhibition (~ 88%) by the wheat germ inhibitor against the
Salivary Amylase, a range of inhibitor concentrations were used against an enzyme
sample. The W.G.I. Type II concentrations ranged from 0----- » 0.136 pg/pL A working
enzyme dilution of 1/200 from the stock enzyme solution was used. The procedure used
was that as specified in Method 2.2.2.

Table 2: % Remaining Acthity values obtained against S. Amylase
dAbs./min

% Remaining

@ 405nm

Activity

0.167

100

0

0.148

89

0.054

0.117

70

0.068

0.093

56

0.082

0.03

18

0.108

0.02

12

0.136

55

[Inhibitor]

TO

V■4-^

(/)

X2

3

</)
</)
03

W

CL
LU

03

c
'(/)

3
(13

E

>^
N
C
03
O
W
03

in

TO
E

o

<

(0

jO

TO

>»

>

E

TO

<

CO

(/)

03

c
o

O)
3

c
o
Q.
3

0)
Q.

if)

£Z
C

C
o

I
c

O

s

c

8
o
o

it:

LU
o
03
03

c

TO
t_
TO

'o
■q
03
It
03

03

C
"O
3

w
CN
sz

Q.

TO
o

AjiAjpv 6u!U!BHJay %

56

o

o

3.3

Assay 3:

Optimisation of the Method by Huang & Tietz on the
CentrifiChem® Analyser, using the substrate EPS and Salivary
Amylase.

The Huang & Tietz Method allowed a dramatic improvement upon the incubation times
compared to O’Donnell & McGeeney Assay. The preincubation step decreased from 25
to 5 mins.

The newly optimised parameters resulted in a change in both the reagent

volumes and E ; S ratios, to produce linear kinetics for the substrate EPS.

The E : S

ratios changed from 1:20 to I; 15.5, while the total reagent volume decreased from 500 pL
to 410 pL. The dilution of enzyme used was 1:180 of the stock enzyme (1 I.U./pL).

Table 3; Absorbance values of S. Amylase with EPS substrate[2.5 mmol/L]
using the Huang & Tietz Method

Absorbance @

Time (sec)

405nm
0

0.643

30

0.705

60

0.767

90

0.827

120

0.888

150

0.948

180

1.006
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Kinetics of EPS Substrate on S.Amylase.

ih 3; Kinetics of S.Amylase using the substrate EPS [2.5 mmol/L] following the technique of Huang Tietz.
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3.4

Assay 4:

Introducing the Effect of the Wheat Germ Inhibitor on the
Salivary Isoenzyme using the Huang & Tietz Method.

The ratio of Inhibitor : Enzyme is 1 ; 1 at a volume of 20 jiL. The Enzyme and Inhibitor
were preincubated at 3TC for 5 minutes. The inhibitor was reconstituted in dH20. The
range of Inhibitor varied from 0 ------- »

0.03 pg/pL where upon the % Remaining

Activity was determined. The formula for calculating % Remaining Activity is as follows;

dAbs./min. of Inhibited Enzyme Activity

x 100

dAbs./min. of Uninhibited Enzyme Activity

The substrate concentration of 2.5 mmolA. was used. The enzyme was diluted 1 ;200 from
the reconstituted stock vial.

Table 4; % Remaining Activity values resulting from the inclusion of W.G.I. T}pe II with
S.Amylase.

dAbs./min.
@ 405nm

% Remaining
Activity

[ Inhibitor]
tig/pL

0.121

100

0

0.114

95

0.002

0.104

86

0.0024

0.049

40

0.006

0.032

27

0.009

0.021

17

0.015

0.014

11

0.018

0.01

8

0.024

0.008

7

0.03
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Effect of W.G.I. Type II on S.Amylase.
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Graph 4: Studying the effect of a range of Inhibitor concentrations upon the Salivary Isoenzyme.
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3.5

Assay 5:

Comparative Inhibition Studies using Two Types of Inhibitor
from the Wheat Germ Seed Triticum aestivum. Type 11 & III.

As previously stated, there are three types of W.G.I., with types II and III being the more
selective for the Salivary isoenzyme. To establish the most efficient inhibitor, both were
tested to study the degree of inhibition using S. Amylase. The Huang & Tietz procedure
(Method 2.2.4) was followed. For direct comparison, the Phosphate Buffer 45 mM,
pH 6.9 (containing 0.5 mmol/L CaCb and 50 mmol/L NaCl) was used to reconstitute the
lyophilised inhibitor pellets of both inhibitors.

Both inhibitors were reconstituted to a

stock concentration of 0.006 pg/pL. The enzyme dilution used was 1:200 from the stock
reconstituted vial.

Table 5: % Remaining Activity values of Inhibitors T\pe II and III over a range of concentrations using
the Salivarv Isoenzv'ine.

dAbs./miii.

% Remaining

405nm (II)

Activity (II)

dAbs./min. @
405nm (HI)

% Remaining
Activity (III)

[ Inhibitor ]
pg/pL

0.180

100

0.155

100

0

0.108

60

0.077

50

0.006

0.070

39

0.067

43

0.009

0.034

19

0.046

30

0.015

0.033

18

0.038

25

0.018

0.028

16

0.036

23

0.024

0.021

12

0.02

13

0.030
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Comparative Inhibition Studies on W.G.I. Types II & III.

100

>
♦3

U

<

O)

c

c

’<5

E
a>

od

0.006

0.009

0.015

0.018

0.024

0.03

[inhibitor] ug/uL

Graph 5: Effect of two different types of Inhibitor, Type
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upon the Salivary Amylase.

3.6

Assay 6:

Optimisation of Inhibitor activity by varying the Inhibitor
Diluent.

The wheat germ inliibitor Type II, as can be seen from the previous experiment proved to
be slightly more selective against the Salivary Amylase and so will be used for the
development of the differential assay.

The wheat germ inhibitor Type II used by

O’Donnell & McGeeney was recommended to be reconstituted in Phosphate Buffer.
However, contradicting references were made to using distilled H2O. For the comparative
studies, as with all further remaining studies incorporating the EPS substrate, the Huang &
Tietz method (2.2.4) will be used. A 1;200 dilution of the reconstituted stock enzyme was
used with both inhibitors.

Table 6; % Remaining Activity values obtained by the two diflerent Inhibitor diluents, dH20 and
Phosphate Buffer against the Salivarj' isoenzyme.

dAbs./min. @

% Remaining

dAbs./min. @

% Remaining

405nm (dHjO)

Activity(dH20)

405nm (Buffer)

Activity (Buffer)

0.121

100

0.180

100

0

0.049

40

0.108

60

0.006

0.032

27

0.070

39

0.009

0.021

17

0.034

19

0.015

0.014

11

0.033

18

0.018

0.010

8

0.028

16

0.024

0.008

7

0.021

12

0.030
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[ Inhibitor ]
pg/pL

Effect of Inhibitor Diluent on Efficiency of inhibition.

0.006

0.009

0.015

0.018

0.024

0.03

[Inhibitor] ug/uL

Graph 6: Effect of the WGI reconstituted in two different diluents upon the Salivary Isoenzyme.
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3,7

Assay 7:

Huang & Tietz Method - Adapted for the CERES 900C Plate
Reader- for Total Amylase Determination.

At a certain stage in the project, the Centrifichem® Analyser began to deviate from the
conventional assay trends, so during the period of instrument adjustment, an alternative
instrument was used, the CERES 900C Plate Reader. Manual pipetting techniques were
used to transfer the solutions to the microtiter plate. Assay parameters, following the
Huang & Tietz Method for the measurement of Total Amylase (Method 2.2.3) were
adjusted accordingly to lie within the specification of the Plate Reader.

Experiments

designed to display linear kinetics for both the S. & P. Amylases were repeated to verify
parameters. The dilution of Pancreatic Amylase was carried out equivalent to that of the
Salivary isoenzyme from pre\dous experiments. A dilution figure of 1:150 was found to
be sufficient to produce linear kinetics.

Table 7; Absorbance values @ 405nm for both the Salivar\' and Pancreatic Amylases on
the Plate Reader Analyser.

Abs. @ 405nm

Abs. @ 405nm

Time

(S.Amylase)

(P.Amylase)

(min.)

0.640

0.490

0

0.738

0.578

1

0.834

0.666

2

0.930

0.753

3
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Graph 7: Linear Kinetics of Isoenzymes on Plate Reader Analyzer.

Time (min.)

Graph 7: Linear Kinetics of Salivary and Pancreatic Amylase on the new Instrument- CERES 900C Analyzer.
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3.8

Assay 8:

Effect of the Wheat Germ Inhibitor Type 11 on Pancreatic
Amylase using the CERES 900C Plate Reader.

The assay parameters were altered for the new instrument to include the inhibitor volume,
method 2.2.5. However all ratios between the reagents and sample remained unchanged.
The inhibitor concentration used against the Pancreatic isoenzyme was 0.018 |J.g/|iL. The
Huang & Tietz method allowed the inhibitor and enzyme to preincubate together for a
period of 5 mins. Separately, the substrate was brought up to reaction temperature. The
enzyme dilution used was 1;150 from the stock reconstituted vial of human Pancreatic
Amylase.

Table 8; Values for the calculation of % Remaining Activity of P. Amylase upon incubation with
0.018 ^g/^iL W.G.I. Type II.

Abs. @ 405iim

dAbs./miii.

Abs. @ 405nm

dAbs./min.

Time

(Enzyme)

(Enzyme)

(Inhibited)

(Inhibited)

(min.)

0.519

—

0.351

—

0

0.616

0.097

0.425

0.074

1

0.707

0.091

0.495

0.070

2

0.798

0.091

0.565

0.070

3

% Remaining Actiwtv Value
P. Amylase

-

76%
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Effect of WGI Type II on P.Amylase.

Time (min.)

Graph 8: The direct inhibition of the Human Pancreatic Amylase by the WGI Type
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3.9

Assay 9;

Generation of a Standard Curve of P. & S.-Amylase using the
Wheat Germ Inhibitor Type II for the Determination of the
Ratio Amylase Isoenzymes with EPS as Substrate.

The activity of the purified human Salivary and Pancreatic Amylases were equal initially.
The W.G.I. concentration used to produce as near to the optimal 88% inhibition on the
Salivary isoenzyme and 19% on the Pancreatic isoamylase, as quoted by Huang & Tietz,
was 0.018 pg/p-L. The EPS substrate was used following the method 2.2.5. A dilution of
1:140 and 1:150 was carried out from the stock Salivary and Pancreatic Amylase
respectively.

The CERES 900C analyser was used following the previous procedure. A standard curve
was prepared by mixing various quantities of Salivary to Pancreatic isoenzymes.

The

activity of both uninhibited and inhibited samples were calculated upon inclusion of the
inhibitor. The % Remaining Activity was plotted against P/T x 100, where P/T was equal
to:
P = Pancreatic Amylase
T = Total Amylase (Salivary + Pancreatic)

Table 9; % Rcmaininc Activity Values for P : S Ratios.

% Remaining

P/T X 100

Activity
19

0

27

10

44

30

60

50

73

70

89

100

69

Standard Curve of Mixed S. & P. Amylases
with WGI Type II.
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Graph 9: Standard Curve obtained by mixing purified Pancreatic Salivary Amylases in ratios in the
range of 0-100 and analyzing the mixtures for Amylase activity in the presence and absence of
inhibitor 0.018 ug/uL
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3.10

Assay 10:

Correlation of Two Methods for Total Amylase Activity
measurement.

A correlation study was carried out using the now newly modified Huang & Tietz Method
and the assay used by the University Hospital Cork (U.H.C.), a Boehringer Mannheim Kit.

The U.H.C. method was based on an enzymatic colorimetric test with 4,6-ethylidene(G7)
-p-Nitrophenyl(Gl)-a-D-maltoheptaoside as substrate. The Boehringer Mannheim enzyme
reaction was based upon the reaction:
a-amylase

5 ethylidene-G7pNP + 5 H2O----------------- 2 ethylidene-G5 + 2 G2 PNP +
2 ethylidene-G4 + 2 G3 PNP + ethylidene-G3 + G4 PNP
a-glucosidase

2 G2 PNP + 2 G3 PNP + 10 H2O--------------------4 PNP + 10 G

Concentration of Reagents:
4,6-Ethylidene-G7 PNP

3 mmol/L

a-Glucosidase

> 29 U/mL

HEPES Buffer

Assay Parameters
R1

250 - 100-0 pL

R2

0 - 20-0 pL

Sample

12-3 pL

Wavelength

405 nm

*

RI = Reagent 1 (Buffer/EnzMne/Substrate), R2 = Reagent 2 (Diluent)

A total of 34 samples of various activities above the normal range were measured by
U.H.C and by the second method, modified Huang & Tietz Method (Method 2.2.3).
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Assay 11:

Optimisation of a Method for Measuring Total Amylase using
the Substrate CNPG3 on the CentrifiChem Analyser.

The method and parameters used were as described by Winn-Deen et al. in Method 2.2.6.
The substrate 2-Chloro-4-nitrophenyl-a-maltotrioside is cleaved in a direct assay by
a-Amylase providing a proportional reading of activity. The [CNPG3] used was 1.63
mmol/L. The dilution of S.Amylase used was 1:140 to produce linear kinetics.

Table 11: Absorbance values of S. Amylase activity wth CNPG3 as substrate.

Time

Absorbance @

(sec.)

405nm

0

0.108

30

0.156

60

0.204

90

0.250

120

0.295

150

0.339

180

0.383

73

Kinetics of CNPG3 Substrate with S.Amylase.

Graph 11; Linear Kinetics of the substrate CNPG3 [ 1.63 mmol/L] produced by S.Amylase.
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3.12

Assay 12:

Study the effect of the Wheat Germ Type II Inhibitor on
S. Amylase using the CNPG3 Substrate.

The Winn-Deen et al. Method was modified to incorporate the selective inhibitor as
specified in Method 2.2.1. The enzyme and inhibitor were allowed to preincubate for 5
mins. @ 37°C. A lag phase of 60 sec. was allowed before the assay was initiated. A range
of Inhibitor concentrations were used to determine the optimum concentration to produce
the quoted 88% inhibition against the Salivary Amylase. A dilution of 1:170 of the stock
reconstituted Salivary Amylase was used. Substrate concentration was 1.63 mmol/L.

Table 12; % Remaining Activity Values obtained over a range of Inhibitor concentrations.

dAbs./min. @

% Remaining

[Inhibitor]

Activity

lAg/pL

0.110

100

0

0.100

91

0.0020

0.090

82

0.0024

0.045

41

0.0060

0.036

33

0.0090

0.027

25

0.0150

0.022

20

0.0180

0.018

16

0.0240

0.016

15

0.0300

405nm
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Effect of the WGI Type W using CNPG3 as substrate.
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Graph 12: Effect of the WGI Type II on S.Amylase activity using CNPG3 as substrate.
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3.13

Assay 13:

Using the W.G.I. Type II Concentration of 0.024 pg/pL, Study
the Effect on Human Pancreatic Amylase with CNPG3 as
Substrate.

The Salivary Amylase was replaced by the Pancreatic isotype and the assay procedure
was repeated following the method 2.2.7. It was necessary to know what the optimum
inhibitor concentration found in the previous assay [0.024 pg/pL] would produce against
the Pancreatic isoenzyme, dilution used 1:140.

Table 13: Absorbance values obtained for Inhibited and Uninhibited Human Pancreatic Amylase.

Abs. @ 405nm
Uninhibited

Abs. @ 405nm
Inhibited

-

(sec.)

0.108

0.097

0

0.156

0.137

30

0.204

0.179

60

0.250

0.224

90

0.295

0.271

120

0.339

0.319

150

0.383

0.368

180

% Remaining Activity
P. Amylase

Time

98%

77

Effect of WGI Type II on P.Amylase

Graph 13: The effect of the WGI Type II (0.024 ug/uL) upon the Pancreatic Isoenzyme.
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3.14

Assay 14:

Generation of a Linear Standard Curve using CNPG3 as
Substrate for Determining Amylase Isoenzymes by Selective
inhibition.

A standard curve was prepared by mixing various proportions of salivary and pancreatic
isoenzymes of equal activity initially and determining the respective activity of each in the
presence of 0.024 pg/p-L W.G.I. Type II. Similar to Assay 14, the curve was plotted as %
Remaining Activity versus P/T x 100.

Enzyme dilution’s of 1:140 were used from the

stock reconstituted (1 I.U./pL) vials of both the Salivary' and Pancreatic enzymes.

Table 14: Standard Curve of the differential measurement of Amylase Isoenzymes.

% Remaining

P/T X 100

Activity
16

0

21

12.5

28

25

36

50

57

75

85

100

79

Standard Curve for Mixed S. & P.Amylases
using CNPG3 as substrate.
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Graph 14: Standard Curve obtained from Mixed Ratios of Salivary and Pancreatic Isoenzymes in the
presence and absence of inhibitor Type II, 0.24 ug/uL.

ao

3.14B Assay 14B:

Correlation Study of the CNPG3 Assay and the U.H.C. Assay

Similar to assay 10, a total number of 32 patient samples all above normal levels were tested, using
samples tested by the University Hospital Cork and by the Wirm-Deen et al. modified method
(Method 2.2.6).

The composition of the U.H.C. method incorporating the Boehringer Mannheim G7 substrate, was
detailed in assay 10. Due to the use of two comparatively different substrates, G7 versus G3, it was
anticipated that there would be a substantial difference between the results obtained for the individual
samples.

Conclusion
Initially
in
Boehringer

assay 10,
Mannheim)

the
used

two

G7

appeared

substrates
to

be

(Olympus
more

similar

and
in

composition than the U.H.C. Boehringer Mannheim G7 substrate
and G3 substrate, CNPG3.
However in assay 10, the results
obtained for the same patient samples were significantly different
and
therefore
had
to
be
adjusted
using
the
calculated
multiplication factor.
A possible explanation is the package insert
of the U.H.C. Boehringer Mannheim Kit as can be seen on page 71.
It

was

observed

that

not

all

the

reagent

compositions

or

concentrations are included.
Therefore the two G7 substrates,
Olympus
and
Boehringer
Mannheim,
could
be
potentially
significantly different.
The second substrate, CNPG3, provided
results similar to the U.H.C. results as can be seen from the axis
used in the graph 14B.
Similar to assay 10, two
values were
chosen
outside the range and applied to
the
predetermined
regression equation, where a line of regression was obtained.
CNPG3 has the potential to be incorporated
into
the clinical
environment, by using the regression equation one can minimize
the alteration of normal and abnormal amylase reference ranges,
while providing the advantage of selectively measuring Amylase
Isoenzyme

activity.

Correlation Curve between U.H.C, Assay
and CNPG3 Assay

U.ILC LUJL
Generation

of

Regression

Line

U.H.C. value=x=200

U.H.C. value=x=7950

y = l .5X-57.8
y=1.5(200)-57.8

y = l .5x-57.8
y=l.5(7950)
y=11867 I.U./L

y=242 I.U./L
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.3.15

Assay 15:

Optimisation of the Method by Uchida, R. et al. for the
measurement of Total Amylase Activity on the CentrifiChem®
Analyser.

A new substrate has been developed by a Japanese research team for the rapid
measurement of Total Amylase activity, N3G5CNP [6.1 mmol/L],
outlined in Method 2.2.8.

This method is

No volume or ratio alterations had to be made to that

developed by Uchida ei al. for use on the CentrifiChem® analyser. A preincubation of 5
mins. @ 37°C was required to bring the reagents up to the desired assay temperature. Lag
phase 2 mins., assay length 3 mins.

Table 15: Absorbance values of S. Amylase using N3G5CNP as substrate.

Absorbance @

Time

405nm

(sec.)

0.144

0

0.206

30

0.271

60

0.337

90

0.405

120

0.473

150

0.538

180

83

Kinetics of Substrate N3G5CNP on S.Amylase.

Graph 15: Linear Kinetics of the substrate N3G5CNP [6.1mmol/L] using S.Amylase.
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3.16

Assay 16:

Study of the Selective Inhibition by the New Inhibitor 6^Deoxymaltotriose upon both Amylase Isoenzymes.

The inhibitor 6^-deoxymaltotriose (DOG3) was reconstituted with dH20 to a
concentration of 0.33 mM. The enzyme : inhibitor was at a ratio of 2 ; 1. The enzyme
and inhibitor were only allowed to mix in the lag phase of the assay for a period of 2
mins. An enzyme dilution of 1:100 and 1:140 were carried out on the reconstituted stock
enzyme vials of Salivary and Pancreatic .\mylase respectively.

Table 16; Absorbance values of both Inhibited (I) and Uninhibited (U), Salivary (HSA) and Pancreatic
Amylase (HPA) isoenzymes.

Abs. @ 405nm

Abs. @ 405nm

Abs. @ 405nm

Abs. @ 405nm

HSA (U)

HSA (I)

HPA (U)

HPA (I)

Time
(sec.)

0.176

0.144

0.177

0.033

0

0.245

0.211

0.159

0.045

30

0.317

0.281

0.205

0.057

60

0.392

0.353

0.250

0.070

90

0.469

0.426

0.296

0.083

120

0.543

0.499

0.341

0.096

150

0.619

0.570

0.387

0.110

180

% Remaining Activity Values
Salivary Amylase

-

96%

Pancreatic Amylase

-

29%

85

Effect of DOG3 (0.33mM) on both S. & P.Amylases
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3.17

Assay 17:

Effect of the Inhibitor DOG3 at a Higher Concentration
(1 mM) upon the Amylase Isoenzymes.

Theoretically, as proposed by Uchida, R. et al. (93), DOG3 should inhibit the HSA and
liPA by 32.1% and 86% respectively. So the concentration was increased from 0.33 mM
to I mM. No other conditions were varied from the previous assay. [Substrate]
6.1 mmol/L. Dilution’s of 1:100 and 1:140 were carried out from the reconstituted stock
vials of Salivary and Pancreatic Amylases respectively.

Table 17: Absorbance values of HSA and HPA both uninhibited (U) and inhibited (I) by
DOG3 (

ImM).

Abs. @ 405nm

Abs. @ 405nm

Abs. @ 405nm

Abs. @ 405nm

Time

HSA (U)

HSA (I)

HPA (U)

HPA (I)

(sec.)

0.184

0.121

0.181

0.011

0

0.254

0.164

0.248

0.016

30

0.330

0.209

0.317

0.019

60

0.406

0.252

0.386

0.022

90

0.482

0.297

0.458

0.025

120

0.558

0.341

0.529

0.029

150

0.634

0.386

0.600

0.032

180

% Remaining Activity Values
Salivary Amylase

-

59%

Pancreatic Amylase

-

5%

87

Effect of Inhibitor DOG3 (ImM) on both Amylase Isoenzymes.

Graph 17: Effect of the DOGS Inhibitor (ImM) against both Amylase Isoenzymes.
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3.18

Assay 18:

Generation of a Standard Curve to Allow for the Automated
Measurement of a-Amylase Isoenzymes with DOG3 as the
Selective Inhibitor.

Similar to the two previous standard curves generated using EPS and CNPG3, various
ratios of salivary isotype to pancreatic amylase were mixed being of equal activities. The
respective activities of the inhibited and uninhibited samples were determined by
calculating the % Remaining Activity after addition of the inhibitor, 0.33 mM. A dilution
of 1:120 was carried out on the P. Amylase reconstituted stock vial while a 1:100 was
used from the Salivary Amylase stock as in the previous assay. [N3G5CNP] 6.1 rnM was
used.

Table 18: % Remaining Activity of S : P samples after addition of DOG3 (0.33 mM).

S/T X 100

% Remaining
Activity
82

100

47

75

44

50

38

25

31

0

89

standard Curve of Mixed S. & P.Amylases with DOGS Inhibitor
(O.SSmM).

Graph 18: Standard Curve obtained from Mixed Ratios of Salivary and Pancreatic Isoenzymes in the presence
and absence of DOG3 Inhibitor (0.33mM).
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3.19

Assay 19:

Automated Measurement of a-Amylase Isoenzymes with 6^Deoxymaltotriose as the Selective Inhibitor by Generation of a
Standard Curve.

The standard curve was created using the inhibitor DOGS at the concentration of 1 mM.
All other parameters and conditions were unchanged from the previous assay. A substrate
concentration of 6.1 mmol/L was used. A dilution of 1:120 and 1; 100 was carried out on
the reconstituted stock enzymes as previously described.

Table 19: % Remaining Actmty values of the S. & P. Amylase Ratios
after inclusion of the inhibitor DOG3 (1 mM).

S/T X 100

% Remaining
Activity
70

100

29

75

15

50

9

25

4

0

91

standard Curve of Mixed S. & P.Amylases with D0G3 Inhibitor
(1mM).

Graph 19: Standard Curve obtained from Mixed Ratios of Salivary and Pancreatic Isoenzymes in the presence
and absence of (1 mM) DOG3 Inhibitor.
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3.20

Assay 20:

Study of the Effect of the Order of Addition of Reagents and
Inhibitor on the Enzyme Activity.

The order of addition of certain reagents can have a significant effect on the enzyme assay.
An inhibitor must be added to the assay where upon it has the largest effect upon the
enzyme or substrate.

In this assay, the wheat germ inhibitor from Triticum aestivum

Type III ( Diluent: Phosphate Buffer) was added to two possible reagents, namely the
substrate and the enzyme to study the importance of ‘Order’. Economic constraints led to
the use of W.G.I. Type III instead of Type II, the better inhibitor as proven in Assay 3.5.
The inhibitor concentration used was 0.018 iig/jaL. The method used for this study was
the now newly modified assay of Huang & Tietz (Method 2.2.6) suitable for the
CentrifiChem Analyser. The enzyme, S. Amylase was used at a dilution of 1:200. [EPS]
2.5 mmol/L.

Table 20: Absorbance values of (1) Enzyme (E). (2) Inhibitor + Enzyme. (I+E) and
(3) Inhibitor + Substrate (I+S).

Time

Abs. @ 405nm

Abs. @ 405nm

Abs. @ 405nm

(sec.)

S.Amy.

I+E

I+S

0

0.857

0

0.931

30

0.960

0

1.028

60

1.061

0.017

1.120

90

1.157

0.039

1.204

120

1.249

0.062

1.285

150

1.336

0.086

1.358

180

1.420

0.112

1.428

% Remaining Activity Values
Inhibitor + Enzyme

=

18%

Inhibitor + Substrate =

86%

93

Comparison of two modes of preincubation with Inhibitor

Graph 20: Study of the effect of two different modes of preincubation of the inhibitor.
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3.21

Assay 21:

Increase of Lag Phase, upon Preincubation of the Substrate
with the W.G.L Type III (0.018 pg/pL).

To attempt to maximise the effectiveness of the inhibition of the wheat germ protein upon
the Salivary Amylase, the lag phase was increased from 5 to 10 mins. As the previous
experiment, W.G.I. Type III was used at a concentration of 0.018 pg/pL. The inhibitor
and substrate [2.5 mmol/L] were still allowed to preincubate for 5 mins. @ 37°C before
introduction of the S. Amylase (Dilution used was 1:200).

Table 21: Absorbance values of enzyme with and without Inhibitor over the assay time of 13
mms.

Time

Absorbance @

Absorbance @

(sec.)

405nm- S.Amy.

405 - + Inhibitor

0

0.744

0.600

30

0.789

0.635

60

0.833

0.668

90

0.876

0.701

120

0.918

0.732

150

0.960

0.763

180

1.001

0.793

% Remaining Activity Values
Inhibitor + Enz^'^me

=

75%

95

Increase in Lag Phase-1 + S Preincubated.

Graph 21: Effect of increasing lag phase for preincubation of inhibitor with substrate.
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3.22

Assay 22:

Effect of the Wheat Germ Inhibitor Type III included with the
EPS Substrate at a Range of Increasing Concentrations.

In an attempt to achieve the same optimum inhibition activities against the Salivary
Amylase, the concentration of the W.G.I. Type III was increased up to 0.337 pg/pL. So
the assay could be related to previous trials, a preincubation time of 5 mins, for the Huang
& Tietz Method was allowed for the inhibitor and substrate to preincubate @ 37°C. An
enzyme dilution of 1:180 was taken from the stock reconstituted vial of 1 I.U./pL.

Table 22: Absorbance values of the effect of the W.G.I. Type III ()ig/|j.L) at varying concentrations on
S. Amylase.

Time

Absorbance

Absorbance

Absorbance

Absorbance

Absorbance

(sec)

S.Amy.

E+I (0.0422)

E+I (0.0844)

E+I (0.169)

E+I (0.337)

0

0.922

0.877

0.498

0.344

0.134

30

1.030

0.939

0.521

0.349

0.135

60

1.119

0.997

0.541

0.353

0.136

90

1.209

1.050

0.559

0.357

0.138

120

1.297

1.100

0.573

0.360

0.139

150

1.381

1.145

0.585

0.362

0.139

180

1.459

1.188

0.598

0.365

0.140

% Remaining Activity Values
Enzyme + I (0.0422 \x^\xL)

=

59%

Enzyme + I (0.0844 |ug/p.L)

=

19%

Enzyme + 1 (0.169 )Lig/}.iL)

=

4%

Enzyme + I (0.337 fig/pL)

=

1%
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Effect of Increasing [Inhibitor] -1 + S Preincubated.
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Graph 22: Effect of increasing Inhibitor concentration, allowing inhibitor and substrate to preincubate.
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3.23

Assay 23:

To find the Optimum W.G.L Type II against both of the
Amylase Isoenzymes allowing the Inhibitor and Substrate to
Preincubate.

The wheat germ inhibitor Type II (Phosphate Buffer as diluent) was used at varying
concentrations (pg/pL) against both Amylase isotypes. Salivary and Pancreatic.

From

which dilutions of 1:220 and 1:192 were taken for optimum conditions. Following the
previous assay, the inhibitor and substrate [2.5 mmol/L] were allowed to preincubate for 5
mins. @ 37C. After this step the Huang & Tietz assay parameters were followed.

Table 2.1: % Remaining Activity values obtained by S. and P. Amylases over a range of W.G.I.
Type II concentrations.

% Remaining

% Remaining

Activity - S.Amy.

Activity - P.Amy.

[Inhibitor]
pg/pL

100

100

0

28

74

0.034

22

65

0.042

21

65

0.045

19

55

0.054

8

50

0.068

7

47

0.085

99

Effect of WGI Type il on both S. & P. Amylases.

Is Amylase
□ Seriesi
■ Series2
P.Amylase

0.034

0.042

0.045

0.054

0.068

0.085

[Inhibitor] ug/uL

Graph 23: To find the optimal WGI concentration for both isoenzymes allowing I + S to preincubate.
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3.24

Assay 24:

Optimisation of the Monoclonal Antibody Kit on the
CentrifiChem using Pancreatic Amylase.

The enz^one / antibody solution and the pancreatic isoenzyme were mixed and
preincubated for 3 mins, at 37°C. In the first incubation step, the activity of the human
pancreatic amylase should not be inhibited by the two different monoclonal antibodies as
they are not specific for the Pancreatic isotype.

After the second incubation with the

substrate EPS, the direct acthaty of the pancreatic a-amylase can be measured.
dilution of P. Amylase used was 1; 110 from the reconstituted stock vial.

Table 24: Absorbance values of Pancreatic Amylase using tlie Boeliringer
Mannheim Monoclonal Antibody Kit. [EPS] was 3 mmoLT.

Time

Absorbance @
405nm

(sec.)
0

0.615

30

0.122

60

0.833

90

0.936

120

1.042

150

1.144

180

1.246

101

The

Kinetics of the EPS A/lonoclonai Antibody Kit with P.Amylase.

Graph 24; Linear Kinetics of Monoclonal Ab, Kit with P.Amylase.
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3.25

Assay 25:

Study the effect of the Boehringer Mannheim Kit on the
Salivary Isoenzyme.

All parameters were as the previous assay. The salivary amylase was substituted for the
pancreatic isoenzyme.

The remaining enzyme activity was measured in I.U./L as

calculated by the formula;

103

Total Assay Volume x

X

Sample Volume

Abs. (2) 405nm

For EPS, the factor was calculated to be equal to the value of 2277.
concentration was 3 mmol/L.

The EPS

To study the effectiveness of the Monoclonal Antibody

against the Salivary Isotype a wide range of enzyme dilutions were used from the stock
reconstituted enzyme.

Table 25: Enzyme Activity values of Salivary Amylase after preincubation
\vith the monoclonal antibody.

Salivary Amylase
Dilutions from stock.

Enzyme Activity
LU./L

1:10 Diln.

437

1:40 Diln.

73

1:60 Diln.

—

1:80 Diln.

—

1:120 Diln.

—

1:160 Diln.

—

1:200 Diln.

—

1:240 Diln.

—

1:300 Diln.

—
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Diln.

Range of S.Amylase Dilutions

Graph 25: The effect of Monoclonal Antibodies over a range of Salivary Amylase Dilutions.
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3.26

Assay 26:

Comparison Study of the Effectiveness of the W.G.I. Type 11
on a Range of salivary Isoenzyme Dilutions.

The optimum commercial concentration determined for the W.G.I. from previous trials
was 0.018 jig/pL. An equal range of enzyme dilutions from a stock concentration of
ll.U/pL were chosen so a direct comparison could be drawn from Assay 25.

The

optimum method used was allowing the direct preincubation of the inhibitor and enzyme
following the assay of Huang & Tietz (Method 2.2.6).

Tabic 26: En2yme activity values (I.U./L) resulting after prcincubation
with 0.018 M-g/p-L W.G.I. Type II.

S.Amylase

Enzyme Activity

Dilutions from stock

I.U./L

1:40 Diln.

471

1:60 Diln.

276

1:80 Diln.

183

1:120 Diln.

104

1:160 Diln.

63

1:240 Diln.

43

1:300 Diln.

24
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1:80
Diln
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Diln.
S.Amylase Dilutions

Graph 26: Effect of the WGI Type III over varying Salivary Amylase Dilutions.
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Assay 27:

Stability Study on the Wheat Germ Inhibitor Type II over 1
Month Duration.

The inhibitor diluent used for this study was the Phosphate Buffer 45 mmol/L, pH 6.9
(containing 0.5 mmol/L CaC^ and 50 mmol/L NaCl). Over the 1 month period, the
W.G.I. Type II solution had to be kept @ 4°C. The Huang & Tietz technique was used
throughout the trial, all conditions being unchanged. Optimum inhibitor concentration of
0.018 p-g/pL was used.

Table 27: % Remaining Activity of S. Amylase resulting from the
presence of the W.G.I. (0.018pg/pL) over 35 days.

Day Number

% Remaining
Activity^

0

100

1

14

2

16.5

3

19

9

19

14

17.6

21

14.7

26

9

35

18.5
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3.28

Assay 28:

Within Run Precision Studies of Huang & Tietz assay using
Patient Samples.

Three patient samples all within the above-normal (< 140 I.U./L) range were tested for
standard deviation (S.D.) and coefficient of variation (C.V. %). The assay was carried
out using the EPS substrate and the Huang & Tietz assay, Method 2.2.6.

Within Run Precision

Mean Serum Amylase

220 l.U./L

877 I.U./L

3794 I.U./L

No. of Assays

20

20

20

Mean Amylase Activity

79 I.U./L

340 I.U./L

1380 I.U./L

S.D.

2.5 I.U./L

8.1 I.U./L

3.1 I.U./L

C.V. %

3.2%

2.3 %

3.1 %

Activity [I.U./L] U.H.C.

EPS Method [I.U./L]
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Assay 29:

Accuracy Studies using EPS as Substrate

The Serodos Control Serum Sample was used to test the accuracy and precision of the
Huang & Tietz Assay using EPS as substrate. The recommended activity of the Serodos
Serum @ 37°C was between 264 - [ 330 ] - 396 LU./I.,

Serodos Control Serum
No. of Assays

20

X

280.55 U./L

S.D.

5.8 U/L

c.v. %

2.1

3.30

Assay 30:

%

Accuracy Studies using CNPG3 as Substrate

The Serodos Control Serum Sample was used to test the accuracy and precision of the
Winn-Deen Assay using CNPG3 as substrate. The recommended activity of the Serodos
Serum @ 37°C was between 620 - [ 776 ] - 930 U/L.

Serodos Control Serum
No. of Assays

:

20

X

:

621 U./L

S.D.

:

13.4 U/L

C.V. %

:

2.2 %
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Assay 31 :

Precision Study on the EPS Standard Curve.

The assay was carried out 10 times repeating the experiment Assay 9. A standard curve
was prepared by mixing various ratios of Salivary and Pancreatic isoenzymes. The %
Remaining Activity after inclusion of the Wheat Germ Inhibitor Type II (0.018 pg/pL)
was calculated for each.

From each of the 10 results for each ratio, the Standard

Deviation (S.D.) and Coefficient of Variation (C.V. %) was calculated to determine if
any, the interference by the Salivary isoenzyme or the inhibitor on the assay.

Amylase Isoenzymes
Amylase Isoenzymes
( No Inhibitor Included)
(+ Inhibitor)
S.D.
C.V. %
Ratio
C.V. %
S. D.
Sample
5.13 X 10-^ 5.7%
4.26X10-^ 6.1 %
P. Amylase 100%
4.6 X 10-3
3.62 X 10-3 5.9 %
5.9 %
90 : 10%
P : dH.O
3.37 X 10-3 6.9 %
4.08 X 10-3 6.6 %
70 : 30 %
P : dH^O
2.35 X 10-3 6.9 %
2.62
X
10-3
6.1
%
50
:
50
%
P : dH.O
1.57 X 10-3 7.9 %
1.64 X 10-3 6.5 %
30 : 70 %
P : dH20
5.19 X 10-3 8.1 %
5.44 X 10-3 6.6 %
90 : 10%
P:S
6.13 X 10-3 11.2%
5.79 X 10-3 6.9 %
70 : 30 %
P:S
6.89
X
10-3
4.93
X 10-3
14.9%
8.7
%
50
:
50
%
P:S
4.6 X 10-3
10.3 X 10-3 13.4%
14.9%
30 : 70 %
P:S
4.09 X 10-3 23 %
S. Amylase 100%
9.69 X 10-3 11.4%
Table 28 A: Standard Deviation and Coefficient of Variation for Amylase
Isoenzymes and the Wheat Germ Inhibitor.

n= 10
P. Amylase = Pancreatic Amylase.
P : dHjO = Pancreatic Amylae and Distilled H2O mixed at stated varying ratios.
P : S = Pancreatic and Salivary isoenzymes mixed at stated varying ratios.
S. Amylase = Salivary Amylase.
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Assay 31:

Contd.

Standard Deviation and Coefficient of Variation for % Remaining Activity.

Sample

Ratio

Mean

S. D.

c.v. %

100%
79.3
P.Amylase
4.877
6.2 %
90
:
10%
79.3
P : S
5.05
6.8 %
78.4
70 : 30 %
5.33
8.2 %
P : S
50 : 50 %
56.5
5.28
9.3 %
P : S
30 : 70 %
40.8
3.67
9.0 %
P: S
20.3
100%
3.65
18%
S. Amylase
able 28 B: Stanc ard Deviation and Coefficient o 'Variation for t le % Remaining
Activity.

n= 10
P. Amylase = Pancreatic Amylase.
P : S = Pancreatic and Salivary isoenzymes mixed at stated varying ratios.
S. Amylase = Salivary Amylase.
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The initial experiments in this project were to optimise the method of O’Donnell &
McGeeney to successfully measure Total Amylase activity.

From the original assay,

several parameters were altered to accommodate the working requirements of the
centrifugal analyser, the CentrifiChem® Analyser. The original assay was developed as a
manual assay, so specific pipettor parameters, reagents ratios and lag phases had to be
predetermined. A second deviation was the change of substrate. With modem technology
and knowledge, a new modem convenient and stable substrate specific for a-Amylase was
developed to replace starch. A new chromogenic maltooligosaccharide of defined chain
length incorporating an enzyme-coupled reaction was developed.

Therefore in assay 1,

the kinetics of the Salivary Amylase isoenzyme were observed after hydrolysing the
substrate EPS to release the free chromophore 4-NP during the 33 minute assay.

This

reaction time was an improvement by 8 mins, from the original assay. As can be seen
from graph 1, the optimum sample : substrate ratio was determined to produce a linear
increase in absorbance values. It was also concluded by calculating the delta absorbance
per minute values (dAbs./min.), that saturation by the enzyme Salivary Amylase did not
occur.

To develop an assay capable of selectively measurir^ the isoenzymes of Amylase
separately, a suitable inhibitor was required.

O’Donnell and McGeeney discovered a

selective inhibitor from the wheat germ seed Triticum aestivum (W.G.I.). There were 3
types of protein inhibitors available, all of differing specificity and sensitivity towards the
Salivary Amylase isoenzyme.

To accommodate the smaller test size, the volume of

reagents was decreased, however all assay ratios were unchanged so that zero
discrepancies could occur. The objective of this assay was to find the optimum inhibitor
concentration to achieve 88% inhibition against the Salivary isotype, as quoted by
O’Donnell & McGeeney.

In assay 3.2, the W.G.I. Type II was tested for its inhibition properties against S.Amylase.
A range of concentrations were used from 0------» 0.136 ng/|aL.

Concentrations were

determined by the volume of inhibitor taken. Volumes were taken that proved easy to
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handle.

Under optimal conditions, Type II should produce -88% inhibition against

S.Amylase.

In table 2, such a level is reached at a concentration of 0.136 pg/pL.

However, this level of inhibition occurred at a higher [I] concentration than recommended
by O’Donnell & McGeeney. The objective was to then try and reduce the concentration
level and retain the specificity.

A new technique by Huang & Tietz was developed to measure Total Amylase Activity. It
suggested immediate advantages over the method of 0 Donnell & McGeeney by using
less reagents and only requiring a 5 minute E + I preincubation step instead of the
previously recommended 25 minutes. To compare the two methods some alterations were
necessary.

A change of substrate was required.

EPS was used to replace their

recommended Maltotetrose substrate and changes were also made to reagent volumes and
ratios. When tested, as can be seen in graph 3, the new modified method of Huang &
Tietz displayed a linear increase in kinetics using the EPS substrate and S.Amylase. Upon
calculation of dAbs./min., the results obtained suggested that the assay parameters were at
optimal volumes and ratios for the measurement of Total Amylase activity.

Similar to O’Donnell & McGeeney, the WGI Type II was .he selective inhibitor of choice
for the development of a selective assay. The volumes of the enzyme and inhibitor were at
a ratio of 1:1.

The major difference between the two methods was with regard to the

incubation period of enzyme and inhibitor. Only a step ot 5 mms. @ 37 C was required
for the enzyme and inhibitor to preincubate before a lag phase of 3 mms. It was during
this first step that the inhibitor bound in a competitive fashion to the enzyme thereby
inhibiting the substrate from binding.

A range of inhibitor concentrations were tested

against the Salivary isoenzyme.

There was a significant improvement upon the inhibition of the sali\'ary isoenzyme using
WGI Type II as can be seen in graph 4. At an [I] of 0.018 pg/pL a level of 89% inhibition
was achieved. This can be directly compared to assay 2. and the 88% level of achieved at
an [I] of 0 136 pg/pL following the technique of O’Donnell & McGeeney. A possible
1 14

explanation for this improvement is the incorporation of the inhibitor at the temperature of
37°C instead of room temperature as used by O’Donnell & McGeeney.
temperature may have enhanced the binding capacity of the inhibitor.

The increased

It was concluded

that the modified Huang & Tietz Method incorporating the WGI had the potential for use
as an automated

differential assay for a-Amylase isoenzymes.

An important factor

remaining was to test the WGI selectivity towards P.Amylase to ensure a definite
specificity difference between the two isoenzymes.

Before the development of the assay could proceed, it was important to ensure the most
selective inhibitor was chosen for the assay. Upon choosing an inhibitor, two important
criteria had to be met:
(a)

Specificity and selectivity of the Inhibitor towards a specific isoenzyme of
Amylase.

(b)

Commercial availability

A.s previously discussed, three different inhibitors have been isolated from the wheat gemt
seed Triticum aestivum

All three are available commercially in a highly purified form

With regard to specificity and selectivity, Types II and III are the more selective.

In

results not shown bui edited out early in the project WGI Type I was examined for its
inhibitors effects on both S. and P.Amylase using the O’Donnell & McGeeney Method. It
was found that at a level of 0.68 pg/pL WGI Type I, a maximum inhibition level of 68%
against the Salivais' isoenzyme and 33% against P. Amylase occurred. At this point Type
II was introduced where immediate improvements were observed

Therefore all further

work incorporating Type I was postponed indefinitely.

The next two assays provide information that is essential for the maximum inhibition
potential of the W'GI and should be analysed simultaneously. Initially the type of WGI to
be used to proMde near optimal inhibitory rates against both isoenzymes shall be
investigated and secondly, the type of inhibitor diluent required to attain again near
optimal results.
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Therefore in assay 5, a comparative study was done on the inhibition properties of WGI
Type II and III against S.Amylase.

For a direct comparison both inhibitors were

reconstituted in a Phosphate Buffer to a stock concentration of 0.006 |ig/pL as
recommended by O’Donnell & McGeeney.

The assay method used was the modified

technique of Huang & Tietz, following the method 2.2.4. From the results (graph 5) it
can be seen that Type II is a slightly more effective inhibitor against Salivary Amylase over
a range of concentrations

This is as expected according to literature, however further

investigative studies have to be carried out to incorporate the Pancreatic isoenzyme.

Different diluents were used to reconstitute the commercially purchased purified a.A.mylase Inhibitor.

In assay 6, two diluents were investigated, Phosphate Buffer, 45

mmol/L, pH 6.9 (containing 0.5 mmol/L CaCb and 50 mmol/L NaCl) and distilled H2O
(dH20)

The better of the two diluents was determined by testing the inhibition of the

WGI Type II on S. Amylase.

The dH20 diluent used to reconstitute the WGI Type II proved to be more effecti\'e in its
inhibition of the Salivary Amylase isoenzyme as can be seen in the results in table 6. The
improvement was not dramatic, however from a commercial viewpoi I i

ki iw higher

inhibition rates occurred at lower inhibitor concentrations and with a cheaper diluent. In
conclusion, dH20 shall be used to reconstitute the inhibitor Type II for further differential
inhibition studies.

Up to this point. Salivary Amylase had been used for all inhibition studies. In assay 7, the
Pancreatic Amylase was used to study the inhibition properties of the WGI Type II.
However, results began to deviate from acceptable preformance using the CentrifiChem
analyser, therefore a new instrument was introduced into the project. The CERES 900C
Plate Reader Instrument not only provided a means to continue the research but it also
allowed previously obtained results to be verified.

The assay parameters had to be

adjusted accordingly to meet certain specifications, however constituent ratios remained
unaltered In assay 7, a suitable working P. Amylase concentration was found to produce

linear kinetics with the EPS substrate. To verify results, a sample of S.Amylase was also
run simultaneously to ensure a continuity of results. The results which were obtained
from the enzyme kinetics suggested that conditions were optimal, therefore the WGI
Type II was introduced into the assay to study effects upon the Pancreatic isoenzyme.

The inhibitor concentration used against the Pancreatic Amylase was 0.018 pg/pL. This
result was chosen from the results obtained in assay 4, table 4. At 0.018 pg/pL, a level of
89% inhibition was achieved against S.Amylase.

Despite a further increase to 0.03

pg/pL, only a further 4% increase resulted, therefore it was not viable to increase [IJ.
This inhibition rate result was also comparable to that obtained b\’ Huang & Tietz.

From table 8, it was concluded that after incubation with 0.018 pg/pL of WGI Type II,
76% of the Pancreatic Amylase activity remained (24% Inhibition). Although, this was
slightly higher than the anticipated result of - 19% Inhibition, it was considered that while
a lower [I] would be less inhibiting towards the Pancreatic isoerrzy'me, so also would it be
towards the Salivary isoenzv'me. As the WGI is not a totally selective inhibitor, it was
therefore decided for a differential assay it would be more advantageous to have the
Salivary isoenzyme activity as near to zero as possible while still maintaining a
Pancreatic enzyme activity of quoted activity.

Having achieved as near as possible to the quoted inhibition rates, a standard curve was
prepared by mixing various proportions of salivary and pancreatic enzymes of equal
activity and determining the respective activity of each in the presence and absence of the
selective wheat germ inhibitor Type II (0.018 pg/pL).

Graph 9, displays a plot of % Remaining Total Activity \ s. P/T ( = P - S) x 100. A curve
was produced to display the relationship between the Huang & Tietz Method and the
selective inhibitor. From this standard curve, patient samples of previously determined
high amylase activity can be remeasured by a single kinetic assay and S : P proportions
can be determined in just 13 minutes. However from the graph, different inhibition

17

rates were obtained for both S. and P.Amylases compared to those rates obtained in
assay’s 4 and 8. Originally, inhibition rates of 89% and 24% were obtained for S. and
P.Amylase respectively. However once the isoenzymes were mixed slightly different rates
were obtained, 84% and 15% respectively.

The question arose regarding the

reproducibility of the experiment. In assay 31, the standard deviation (S.D.) and
coeflBcient of variation (C.V.%) of the standard curve was examined. From table 28A it
can be seen, the S.D. and C.V.% of P.Amylase without the inhibitor at varying
concentrations was less than 6.6%. Upon addition of the WGI, the C.V.% was increased
slightly.

Upon inclusion of the S.Amylase with P.Amylase, the C.V.% increased

significantly. This was then heightened with the inclusion of the inhibitor. This would
suggest firstly that the S.Amylase interferes with the assay and secondly, the inhibitor
reacts with the sa.ivary isoenzyme in a manner to be yet examined as future work to
decrease the overall precision and accuracy of the standard curve (see table 28B).

The adaptability of this assay in an already commercially competitive market was then
analysed. A correlation study was carried out in assay 10, between this new assay and an
assay already existing in a clinical environment from the University Hospital Cork
(U.H.C.). The clinically used substrate was an EPS substrate of a different composition
and the assay parameters were changed, therefore a direct comparison of the two G7
substrates could not be carried out. The assay involved comparing results from 34 patient
samples using the assay results from U.H.C. and the Huang & Tietz Assay.

Methods could be interconverted by use of a regression equation which determined a
multiplication factor of 0.364. A correlation coefficient of 0.996 was calculated for the
comparability of the two methods. The calculation of this figure would offer the clinical
environment the opportunity to change methods and during the period of adjustment,
‘new’ enzyme activity values could be compared to ‘old’ values with respect to reference
intervals. Both assays were of the same assay length, however the modified Huang &
Tietz method offered the advantage of selective measurement of the isoenzymes directly

In assay 11, a second substrate for measuring Total Amylase activity was used, 2-chloro4-nitrophenyl-a-maltotrioside (CNPG3).

The conditions and parameters for this direct

colorimetric assay had to be optimised for the CentrifiChem Analyser. Winn-Deen et al.
suggested an enzyme ; substrate ratio of 1 ; 60 which was found not to produce linear
kinetics on repeated studies, however a suitable assay resulted at a ratio of 1 . 40
respectively.

As can be seen in graph 11, the enzyme produced a linear increase in absorbance over the
assay duration of three minutes and meanwhile the substrate retained constant dAbs./min.
values verifying optimal enzyme : substrate ratios and linear kinetics.

The WGI was included into the assay trial to study the inhibition effects using CNPG3 as
substrate (Assay 12),

The original Winn-Deen et al. assay was developed for the

measurement of Total Amylase activity only, therefore it was not known how the WGI
would inhibit the assay. A range of inhibitor concentrations were used against the salivary
isoenzyme. As in the Huang & Tietz technique, the enzyme and inhibitor were allowed to
preincubate for 5 minutes at 37°C.

A lag phase of only 60 sec. was necessary for the

enzyme to reach linear kinetics as previously determined

v^as due directly to the lack

of auxiliary enzymes present in the substrate reagent. Since the WGI was being utilised
again as the selective inhibitor, the optimal inhibitor rates quoted by Huang & Tietz, were
tested.

However these references were just as a guide to the potential inhibition rates

possible against both isoenzymes.

From the results it was observed that to achieve the -88% inhibition against the Salivary
isotype, an inhibitor concentration of 0.024 pg/pL was required. At this concentration, a
level of 84% inhibition was achieved. Compared to the Huang & Tietz Method using the
EPS substrate, an increase in the inhibitor concentration is required to achieve the near
optimum inhibition rate against S.Amylase.

However, a subsequent advantage is the

direct decrease in assay duration from 13 mins, to 9 mins, as a result. In a commercially
competitive market this is a significant advantage in favour of the Winn-Deen et al.
1 19

modified method.

It was then decided to study the effect of the WGI Type II on the Pancreatic isoamylase
using CNPG3 as the substrate. The Pancreatic isotype was substituted for the Salivary
isoenzyme and the assay was repeated using 0.024 |ig/|J.L WGI in Assay 13. From the
table it could be deduced that 0.024 P-g/jaL allowed the Pancreatic Amylase to retain 98%
activity. Overall, the CNPG3 assay required less reagents, a shorter preincubation period
for enzyme and inhibitor and was available commercially in a liquid stable form therefore
automatically becoming more user friendly. Therefore from both these preliminary results
and the practical assay procedure, the CNPG3 assay appeared to be an improvement upon
the EPS assay.

In assay 14, a standard curve was generated as in assay 9, where various proportions of
Salivary and Pancreatic isoenzymes were mixed and their activities measured in the
presence and absence of WGI Type II (0.024 pg/pL). From the table, it can be seen that
there were similar kinetics occurring again as seen in assay 9. In assay 12 and 13 the
inhibition levels for S. and P.Amylases were 84% and 2% respectively.

After

observations from assay 9, it was expected that inhibition levels would be slightl>
once the isoenzymes were mixed. This was found to be repeated, as can be seen from
table 14.

Inhibition levels of 84% and 15% were obtained for S. and P.Amylase

respectively. This ruled out any suspected interference by the substrate. Questions arose
as to the method of extraction of purified S. and P. Amylase. Unfortunately, due to the
expense of the purified sample of P. Amylase, it was not possible to obtain a subsequent
sample from an alternative supplier to examine this possibility.

On direct comparison between table 9 and 14, the end-point results at zero P / T x 100
and 100 P / T x 100 are quite similar, both giving the near quoted optimum inhibition
values for Triticum aestivum.

The inhibition results obtained by O’Donnell &

McGeeney and by Huang & Tietz combined were quoted to being between 87-90% and
19-20% for S. and P.Amylase respectively. Therefore individually, assay 9, lay between
120

these end parameters and assay 14, which was not originally developed by Winn-Deen et

al. as a selective assay, lay just below these ranges. However, overall the EPS Standard
Curve produced a better and more even spread of results than the CNPG3 curve. On the
positive side of the CNPG3 assay , the assay was more rapid and a smaller volume of
reagents was required. The lack of auxiliary en2^ymes produced a more stable substrate
which was developed as a liquid substrate, therefore making the assay more user friendly
in a commercially competitive market. Nevertheless both methods provided an
alternative assay for the determination of a-Amylase isoenzymes.

Assay 14B was similar to assay 10 where a correlation curve was deduced between 33
U.H.C. values and CNPG3 values. A multiplication factor of 1.5 was calculated by a
regression equation which related the two assays and a correlation factor of 0.997 was
estimated. Again the adaptability of clinical laboratories to the ‘new’ method would be
made easier by the calculation of the determined multiplication-factor.

A

new

substrate,

2-Chloro-4-nitrophenyl-6^-azido-6^-deozy-{3-maltopentaoside

(N3G5CNP) was recently developed by Uchida et al. for the measurement of Total
Amylase Activity. In assay 15 the assay

inodified and optimised for direct

measurement of a-Amylase on the CentrifiChem® Analyser. A preincubation of 5 mins.
@ 37°C was allowed to bring up the reagents to the desired temperature. A lag phase of
2 mins, preceded the start of the 3 minute assay.

As can be seen from the graph, the Salivary Amylase achieved linear kinetics with the
new substrate N3G5CNP over the assay length of 3 minutes.

To verify the rate of

change of the substrate throughout the assay, the dAbs./min. was determined, in results
not shown, and showed that the substrate retained linear dAbs./min. values and so
proved the assay had been optimised for the determination of Amylase activity. Once
this was ascertained, the specific synthetic selective inhibitor was introduced into the
assay.
With all

of the

assay parameters optimised the novel
121

selective

inhibitor

6 -

eoxymaltotriose (DOG3) was introduced into the reaction in Assay 16.

It was

^commended by Uchida et al. to use an Inhibitor concentration of 0.33 mM to achieve
lie inhibition level of P.Amylase and S.Amylase of 86.9% and 32.1% respectively. All of
he reagents were brought to the desired temperature prior to reaction for 5 mins during
vhich time the enzyme and inhibitor were allowed to preincubate. The enzyme, inhibitor
nixture and the substrate were then mixed in the lag phase for 2 mins, and then the assay
started.

From the table 16, it can be deduced that the inhibitor DOG3 (0.33 mM) inhibited the
salivary- and pancreatic-isotypes by 4% and 71% respectively.
than the reported inhibition results.

This result was lower

It was clear that the DOG3 inhibitor was not as

selective as the W.G.I. Type II, however selective specificity was produced between the
two isoenzymes. Therefore, to attempt to increase the selectivity and inhibition rates,
the concentration of the DOG3 was increased to 1 mM and the experiment was repeated.

From table 17, it was calculated that 1 mM DOG3 inhibited the Salivary and Pancreatic
isoenzymes by 41% and 95% respectively. This was closer to the values as observed by
Uchida c. c*.'. fci over three times recommended optimum concentration of inhibitor. It
was of interest to follow up on the standard curves generated by the two inhibitor
concentrations against the amylase isoenzymes. It would also be of interest to observe if
similar inhibited activity discrepancies would arise with regard to the mixing of the
isoenzymes and inhibitor as seen in assay s 9 and 14.

In assay 18, similar to assay 9 and 14, Salivary and Pancreatic isoenzymes of equal
activity were mixed in various ratios both in the presence and absence of DOG3 inhibitor
(0.33 mM). From table 18, it can be seen that at 100% Salivary isoenzyme, a relatively
high % of activity remained. However the activity with 100% Pancreatic Amylase was
very high 31% Remaining Activity. This would lead one to conclude that DOG3 was
not selective enough for one isotype over another at the concentration 0.33 mM. Similar
to the standard curves using EPS and CNPG3, activities of the mixed isoenz>Tnes,
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without the inhibitor, varied slightly from the theoretical combined activity. Due to the
fact that a different substrate, inhibitor and assay times were utilised, this verifies the
possibility of the problem arising from the individual enzymes.

To improve upon the inhibition results, the assay was repeated to try and improve the
sensitivity of the standard curve by using the inhibitor DOG3 at a higher concentration of
ImM in Assay 19.

As can be seen graphically, a smooth curve is produced, which

automatically suggests it’s potential use as a standard cuiwe. Correspondingly the zero
S / T value had decreased, from 31% to 4%. Individually, this was an improvement
upon the quoted inhibition rate against the pancreatic isoenzyme, from 86.9% to 96%
inhibited.

With respect to the salivary isoenzyme, there was just a slight increase in

activity by 2%, however overall it appeared to be an improvement on the original Uchida

et al. method. There is a potential use for the DOG3 selective inhibitor and the specific
substrate, N3G5CNP, in a clinical environment.

The high inhibition rate against the

P. Amylase almost produces a 100% knock-out effect. Further work could be carried out
to try and attempt a full inhibition of the pancreatic isoenzyme utilising the selective
inhibitor DOG3.

So as the optimum assay for selective measurement of a-Amylase

isoenzymes, both the EPS and the CNPG3 Assays were the piCiCir^d choice for further
studies.

A question of the order of addition of reagents to the enzyme assays arose with regard to
the assays concerning Olympus Diagnostica GmbH, namely the assay s incorporating the
substrates EPS and CNPG3. The lesser the manual input into the assay, the greater the
convenience, therefore the more commercially competitive the product. In the case of
incorporation of an inhibitor, it appeared to be all the more relevant, as the inhibitor was
being stored separately.

In assay 25, two comparative types of assays were set up. The first allowed the enzyme
and inhibitor (W.G.I. Type III) to preincubate for 5 minutes @ 37°C and the second
comprised of the inhibitor and substrate to be preincubated together and treated in the
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same manner.
previous assays.

The modified Huang and Tietz method was followed as described in
WGI Type III was used for these experiments due to the fact that

literature had commented upon the importance of the order of addition of reagents and it
was clearly recommended to preincubate the enzyme and inhibitor together before
inclusion of the substrate. Therefore as there was a financial restraint upon the project, it
was not feasible to use the remaining stocks of WGI Type II as success in this field of
experimentation was unlikely. The incorporation of the WGI Type III would still give
relatively similar results as Type II as was previously verified in assay 5 therefore Type
III would prove a useful indicator of any impending success.

From the absorbance

readings in table 20, it clearly displays the lack of effect of the inhibitor when
preincubated with the substrate.

This verifies published data.

A value of 86%

Remaining Activity (14% Inhibition) was obtained upon preincubating the inhibitor and
the substrate together for 5 mins.

This is compared to the 18% Remaining Activity

(82% Inhibition) for activity after preincubation of the enzyme and inhibitor together for
5 mins, after which time the substrate is introduced into the reaction.

A possible

explanation of this is the type of mode of inhibition used by the wheat germ inhibitor.
The WGI is a competitive inhibitor and displays the kinetics of:

E+S

-> E + P

-> ES

+
I

El
*E=Enzyme, S=Substrate, ES=Enzyme; Substrate Complex, P=Procluct, I=Inlubitor.

The inhibitor and substrate must have structurally similar characteristics to prevent the
substrate entering the enzyme’s active site.

In the situation where the inhibitor and

enzyme are allowed to preincubate for the 5 mins, prior to addition of the substrate, the
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inhibitor has time to bind to the enzymes active site without competition by the substrate.
Therefore upon addition of the substrate, the substrate cannot remove the inhibitor
already bound resulting in the inhibition of the enzyme.

In the second situation, the preincubation of the inhibitor and substrate, no inhibition is
occurring as the inhibitor is only selective for the enzyme, therefore when the enzyme is
introduced to the reaction, the substrate and inhibitor are both competing simultaneously
for a specific number of active sites on the enzyme. As the % Remaining Activity value
is so high, it is clear that as the substrate is at a much higher concentration than the
inhibitor, then most of the enzymes active sites are being bound by the substrate,
allowing the reaction to occur.

To cover all possibilities for the inclusion of the inhibitor with the substrate as an
alternative reagent foiTnulation an increase in the lag phase was proposed in Assay 21.
The lag phase was increased from 5 mins, to 10 mins, thereby allowing the substrate and
inhibitor WGI Type III to preincubate for longer. However as can be seen in graph 21, a
75% Remaining Activity was retained ruling out an alternative mode of inhibition. The
substantial increase in the lag pliuti, . . as not a feasible solution as this would have ruled
out it’s use in emergency cases. A more probable solution was to try an increase in the
inhibitor concentration.

In Assay 22, the W.G.I. Type III concentration was increased up to 0.337 pg/pL against
the Salivary Amylase allowing a lag phase of 5 minutes for the inclusion of the inhibitor
with the substrate.

As with previously used concentrations, values were used that

provided volumes easy to handle. From the results it was calculated that an inhibitor
concentration of 0.169 pg/pL and 0.337 pg/pL both resulted in Salivary Amylase
activities of less than 4%. As it was discovered in assay 5 that inhibition properties of
W.G.I. Type III were not as effective as Type II, the assay was repeated to find the
optimum concentration of inhibitor Type II effective against both isoenzymes when
included with the substrate EPS.
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In assay 23, a range of inhibitor Type II concentrations were used varying from 0.034
|ig/|iL to 0.085 fJ-g/pL. A lag phase of 5 mins, was allowed. As can be seen from table
23, the correlating % Remaining Activity values at varying inhibitor concentrations for
both isoenzymes, the only concentration which looked useful was 0.068 pg/pL. At this
concentration 50% of the Pancreatic Amylase was inhibited and nearly all of the Salivary
Amylase as developed by Courtois & Franckson (83). Therefore if a standard curve was
generated at this inhibitor concentration, than any Pancreatic activity value calculated
from the curve could be doubled to relate it to the patient serum amylase sample.
However, the advantage gained by the increase in inhibitor concentration is not viable
when compared to the results obtained in Assay‘s 9 and 14.

In assay 24, a Boehringer Mannheim Kit composed of Monoclonal Antibodies for
Salivary Amylase was adapted and tested for the CenfrifiChem® Analyser. The specific
monoclonal antibodies are designed to specifically recognise the salivary isoenzyme only.
In the trial, the Human Pancreatic Amylase was used to ensure linear kinetics with the
EPS substrate provided in the kit. As can be seen from graph 24, the enzyme activity
increased linearly during the enzyme assa^ j^roviag optimal enzyme conditions. Only by
calculating the dAbs./min. and observing the linear increase in absorbance values can one
conclude that the pancreatic amylase is being uninhibited by the two antibodies.

In the next two assays, 25 and 26 a test of the inhibition effectiveness over a range of
Salivary Amylase concentrations was determined for both the W.G.I. and the
Monoclonal Antibody Solution. A more direct comparison cannot be carried out due to
the differences in substrate composition.

In the Boehringer Mannheim Kit, the activity

of purified human Salivary a-Amylase is inhibited by two different monoclonal
antibodies which do not affect Pancreatic a-Amylase.

In graph 25, the monoclonal

antibodies completely inhibit the Salivary a-Amylase at a dilution of 1:60 of the total
stock vial lU/pL. By a direct comparison, the W.G.I. Type II (0.018 pg/pL) does not
completely knock out all enzyme activity even at a dilution of 1:300 (graph 26). The
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resulting conclusion would be that the monoclonal antibodies are more selective and
specific for Salivary Amylase than the wheat germ inhibitor as identified in previous
assays.

However, the expense of the kit may be a drawback for the small clinical

laboratories, whereas the W.G.I. offers a good indication of S : P ratios in patient
samples, while being more economically viable.

In Assay 27, a stability study test was carried out on the W.G.I. Type II over a 35 day
period. The recommendation that accelerated and normal stability studies would be
carried out was requested by Olympus Diagnostica GmbH. It is recognised by both
international Pharmaceutical and Diagnostic industries that, if a sample retains it's
activity after storage @ 37°C for a period of one month, then the expiry date can be
predicted to being one year (see appendix). For literature regarding accelerated stabilitystudies, see appendix at the end of the discussion obtained from industry to verify this
data. On day zero. Total Salivary Amylase activity was determined and taken as 100%
Activity. Tliroughout the next 35 days the inhibiting powers of the wheat germ protein
did not vary significantly while being stored at 4°C.

An accelerated study of the

inhibitor kept at 37°C failed after 1 day, thereby through deduction it was concluded
that the inhibitor would not keep in solution for anytime beyond 2 months.

This study was purely carried out to test the commercial storing of the protein, to study
if the inhibitor would keep active if mixed and packaged with the substrate in solution.
As this failed, the inhibitor would have to be packaged in a separate vial ready for
reconstitution.

The final three assays 28, 29 and 30, were studies on the accuracy and precision of the
methods EPS and CNPG3. In assay 28, a within run precision study was carried out
using patient samples all in the above nomial range. A statistically significant number
of samples were analysed. In all three samples a C.V. % of less than 5% was obtained.
Assay’s 29 and 30, were examining accuracy studies of the two methods, incorporating

27

EPS and CNPG3 using a commercially available control serum sample.

In both

methods, a % coefficient of variation of less than 2.3 % was obtained, proving that both
assays provided reproducible results.

28

-

9

-

TABLE 1.
Shelf Life Equivalency Table
•-TEMP .

0

.

DAYS

WEEKS

4.0
15.0
25.0
37.0
41.0
45.0

182.625
45.611
14.152
3.834
2.536
1.695

26.000
6.501
2.015
0-546
0-361
0.241

4.0
15.0
25.0
37.0
41.0
45.0

365.250
91.322
28.303
7.667
5.072
3.391

52.000
13.001
4.029
1-092
0.722
0 - 483

4.015.0
25.0
37.041. o'
45.0

547.875
136.983
42.455
11.501
7.609
5.086

4.0
15.0
25.0
37.0
41.0
45.0
4.0
15.0
25.0
37.0
41.0
45.0

MONTHS
6.000
1-500
0.465
0.126
0.083
♦'0.056

YEARS
0.500
0.125
0.039
0.010
0-007
0.005

20
20
20
20
20
20

Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
KcAl/Mol

12.000
3.000 *
0.930
0.252
0.167
0-111

1.000
0.250
0.077
0.021
0.014
0.009

20
20
20
20
20
20

Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol

78 - 000
19-502
6.044
1.637
1-0*8 3
0.724

18.000
4.500
1.395
0.378
0.250
0.167

1.500
0.375
0.116
0.031
0.021
0-014

20
20
20
20
20
20

Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol

730.500
1821644
56-606
15.335
10.145
6.781

104.000
26.003
8.059
2.183
1-444
0.965

24-000
6.001
1.860
0.504
0.333
0.223

2-000
0-500
0.155
0.042
0.028
0.019

20
20
20
20
20
20

Kcal/Mol
Kcal/Mol
Kcal/Mol' - Kcal/Mol
Kcal/Mol
Kcal/Mol.

913.125
228.305
70.758
19.169
12-681
8.477

130.000
32.503
10.074
2.729
1-805
1.207

30.000
7.501
2.325
0-630
0-417
0.279

2.50 0
0.625
0.194
0.052
0.035
0.023

20
20
20
20
20
20

Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol-

4.0 1095.750
15.0
273.966
25.0
84.909
37.0
23-002
41.0
15.217
45.0
10.172

156.000
39.004
12.088
3 . ^75
2-166
1.448

36.000
9-001
2.790
0.756
0.500
0.334

3.000
0.750
0.232
0.063
0.042
0.028

20
20
20
20
20
20

Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol

4.0 1278.375
15.0
319.627
25.0
99.061
37.0
26.836
41.0
17.753
45.0
11.868

182.000
45.505
14.103
3.821
2.528
1.690

42-000
10-501
3.255
0.882
0-583
0.390

3.500
0.875
0.271
0.073
0-049
0.032

20
20
20
20
20
20

Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol
Kcal/Mol

f'
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Appendix
Results from Assay 31
P. Amylase (100 %)
clA/min.
0.094
0.085
0.088
0.091
0.093
0.095
0.079
0.083
0.087
O.09
P. Amylase (100%) +
Inhibilor
clA/min.
0.077
0.069
0.069
0.072
0.074
0.072
0.062
0.066
0.069
0.07
3. Amylase (100%)
clA/min.
0.098
0.09
0.078
0.082
0.088
0.069
0.094
0.072
0.089
0.093
S. Amylase (100%)+
Inhibitor
dA/min.
0.025
0.017
0.011

0.016
0.022

0.017
0.016
0.013
0.02

P : S Amylase(90; 109r)
dA/min.
0.084
0.081
0.088
0.092
0.078
0.089
0.079
0.085
0.076
0.078

P : S Amylase(50:50%)
dA/min.
0.078
0.088
0.076
0.081
0.072
0.083
0.079
0.068
0.09
0.074

P : S Amylase
(90:10%)+!
clA/min.
0.066
0.062
0.07
0.075
0.062
0.066
0.055
0.058
0.053
0.055

P : S.Amylase
(50:5070+1
dA/min.
0.047
0.05
0.046
0.049
0.043
0.042
0.035
0.039
0.05
0.044

P : S Amylase(70:30%)
dA/min.
0.092
0.081
0.087
0.079
0.083
0.088
0.09
0.075
0.089
0.078

P : S Amylase(3():7()7
dA/min.
0.081
0.072
0.077
0.064
0.088
0.092
0.067
0.071
0.089
0.066

P : S Amylase
(70:30%) +1
dA/min.
0.055
0.056
0.064
0.049
0.05
0.052
0.06
0.049
0.063
0.047

P : S Amylase
(30:707) + I
dA/min.
0.039
0.027
0.033
0.025
0.033
0.034
0.027
0.033
0.035
0.026

0.018
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Assay 31 Contd.

P.Amylase + dHA)
(90:10%)
d A/min.
0.082
0.078
0.084
().08
0.074
0.075
0.068
0.079
0.08
0.076

P.Amylase + dH4)
(50;50%)
d A/m in
0.045
0.047
0.042
0.042
0.046
0.04
0.044
0.041
0.042
0.039

P.Ainylase + dH%) + I
(90:10%)
d A/min
0.067
0.062
0.066
0.062
0.057
0.06
0.056
0.062
0.065
0.06

P.Amyla.se + dHA) + 1
(50:50%)
d A/min
0.035
0.037
0.034
0.034
0.037
0.031
0.035
0.033
0.032
0.03

P.Amylase + dHX)
(70:30%)
dA/min
0.058
0.062
0.066
0.06
0.056
0.059
0.068
0.067
0.062
0.059

P.Amylase + dH-O
(30:70%)
dA/min
0.026
0.028
0.027
0.026
0.023
0.024
0.026
0.025
0.025
0.023

P.Ainylase + dH.O + I
(70:30%)
dA/min
0.044
0.049
0.051
0.048
{).044
0.048
0.054
0.052
0.048
0.045

P.Amyla.se + dH-O
(30;707r)
dA/min

o.o:
0.022

0.022
0.02

0.018
0.018
0.021

0.019
0.019
0.018
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The O’Donnell and McGeeney Method, developed in the 1970’s was based on a
saccharogenic assay to measure both Total and individual Amylase Isoenzyme activity.
This technique was the basis of up-dating the assay using modem chromogenic modified
oligosaccharides, namely G3 and G7 oligosaccharide substrates. The inhibitor used was
that as specified by O’Donnell & McGeeney, the Wheat Germ Inhibitor from the Triticum

aestivum seed. With several modification’s to the method, the EPS substrate provided a
very useful standard curve for the analysis of patient samples directly. A second technique
provided by Winn-Deen et al. was found to be previously developed for total amylase
measurement using a G3 substrate. However, the assay was taken a step further and the
wheat germ inhibitor was introduced into the assay to attempt to develop a selective assay
for amylase isoenzyme measurement. Tliis proved to also be a potentially effective assay
for the analysis of patient samples of abnormally high levels of Amylase activity.

Overall, both techniques are rapid, simple and easily automated, resulting in the
differentiation of both isotypes of Amylase. Of the two, the CNPG3 Assay would be the
method of choice for a selective measurement of Amylase Isoenzymes. CNPG3 has the
obvious advantage of not requiring auxiliary enzymes, thus providing a direct assay,
shorter assay times and requiring smaller sample ?r)d reagent volumes. The substrate was
also available in a liquid stable form, increasing the ease of use for the technical staff in a
clinical environment. The inhibition range from the Standard Curve obtained is equivalent
to the EPS Assay, so both assays were optimised to the full inhibiting potential of the
W.G.I.

As an interesting contrast a newly developed substrate, N3G5CNP, was obtained from
Japan with a novel selective inhibitor DOG3. DOG3 was a Pancreatic Amylase inhibitor.
This was to supply an alternative perspective upon the role of an inhibitor in a colorimetric
assay.

Assay times lay between the EPS and the CNPG3 Assay.

WTile the inhibition

range for the DOG3 inhibitor at both concentrations, 0.33 mM and 1 mM, did not display
as wide a range as the W.G.I. for both EPS and CNPG3, the resulting standard curve for
1 mM DOG3 proved smooth and potentially useful, as the P. Amylase activity was
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diminished to 4% remaining activity.

Further work could be carried out to obtain

negligible Pancreatic activity, thereby increasing the potential use of the standard curve.
Comparison tests were carried out against a newly developed Selective assay based upon
the incorporation of monoclonal antibodies specific for the Salivary Amylase and the EPS
Assay incorporating the W.G.I.

The results displayed 100% sensitivity for the salivary

isotype at the dilution’s that have been utilised throughout this project, i.e. between the
dilution factors of 1 ; 160 and 1: 240. At these dilution’s and larger, the W.G.I. failed to
completely inhibit the salivary isoenzymes activity. However, while these results proved
conclusive in favour of the Boehringer Mannheim Monoclonal Antibody Kit, the
production of the antibodies is very expensive and specialised.

The CNPG3 Assay

however, is cheap, rapid and provides an effective tecimique for a-Amylase isoenzyme
measurement.

Further work for the future could be carried out to try and find new selective a-Amylase
inhibitors with greater selectivity for one individual isotype.

Preliminary studies were

carried out incorporating the DOG3 inhibitor with CNPG3 and EPS.
inhibition of the P.Amylase occurred.

However, no

Activity results obtained were similar to those

vViLiiv>ut the inclusion of the DOG3 inhibitor. No further work was carried out due to the
requirement by Olympus Diagnostica GmbH that the inhibitor should be commercially
available.

A thorough investigation was carried out by ACI, Co. Tipperary, which

revealed that the Japanese researcher was the only producer to date, of the selective
inhibitor. Due then to time limitations, no more DOG3 was able to be requested from
Japan to continue investigations.

However it is highly probable that synthetically

produced specific substrates with specific selective inhibitors harbours the potential for
future investigations and development of a differential assay for Amylase Isoenzymes.
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